Document:

<PAGE>   1
                                                                    Exhibit 10.6

                              EMPLOYMENT AGREEMENT

     This Agreement is made by and between diaDexus, Inc. (the "Company"), and
Patrick Plewman ("Executive") effective as of June 4, 2000.

     1.   Duties and Scope of Employment.

          (a)  Positions; Employment Term; Duties. Executive's employment with
the Company commenced in October 1997, and as of June 4, 2000, the Executive was
appointed Chief Executive Officer, President, Chief Operating Officer and
Secretary of the Company, and he continues to be employed in such capacities in
accordance with the terms hereof. The period of Executive's employment hereunder
is referred to herein as the Employment Term. During the Employment Term,
Executive shall render such business and professional services in the
performance of his duties, consistent with Executive's position within the
Company, as shall reasonably be assigned to him by the Board of Directors (the
"Board").

          (b)  Obligations. During the Employment Term, Executive shall devote
his full business efforts and time to the Company. Executive agrees, during the
Employment Term, not to actively engage in any other employment, occupation or
consulting activity for any direct or indirect remuneration without the prior
approval of the Board; provided, however, that Executive may serve in any
capacity with any civic, educational or charitable organization, or as a member
of corporate Boards of Directors or committees thereof upon which Executive
currently serves, without the approval of the Board; provided, further that
Executive may devote a reasonable amount of time to managing his family
investments.

          (c)  Paid Time Off. Until the fifth anniversary of his commencement of
employment, which for purposes of vesting under this Section 1(c) shall be
measured based upon his initial employment by SmithKline Beecham Corporation,
Executive shall be entitled to twenty (20) days per year of paid time off.
Thereafter, Executive shall be entitled to twenty-five (25) days per year of
paid time off. For purposes of this Agreement "paid time off" includes vacation,
personal time off, sick leave, family illness, bereavement leave and religious
holiday observances. During such paid time off periods, Executive shall not be
relieved of his duties under this Agreement and there will be no abatement or
reduction of Executive's compensation hereunder.

     2.   Employee Benefits; Indemnification Agreement. During the Employment
Term, except as otherwise provided herein, Executive shall be eligible to
participate in the employee benefit plans maintained by the Company that are
applicable to other senior management to the full extent provided for under
those plans. Upon his commencement of employment with the Company, Executive
entered into an indemnification agreement comparable in form and substance to
indemnification agreements entered into by and between the Company and its
executive officers.

                                       1

<PAGE>   2

     3.   At-Will Employment. Executive and the Company understand and
acknowledge that Executive's employment with the Company constitutes at-will
employment. Subject to the Company's obligation to provide severance benefits as
specified herein, Executive and the Company acknowledge that this employment
relationship may be terminated at any time, upon written notice to the other
party, with or without good cause or for any or no cause, at the option either
of the Company or Executive.

     4.   Compensation.

          (a)  Base Salary. While employed by the Company, the Company shall pay
the Executive as compensation for his services a base salary at the annualized
rate of $245,000 (the "Base Salary"). Such salary shall be paid periodically in
accordance with normal Company payroll practices and subject to the usual,
required withholding. Executive's Base Salary shall be reviewed annually by the
Compensation Committee of the Board for possible increases in light of
Executive's performance and competitive data.

          (b)  Bonuses. Executive shall be eligible to earn a bonus. Executive's
performance shall be evaluated by the Compensation Committee of the Board based
upon performance criteria specified by that committee. The payment of any bonus
under this Section 4(b) shall be subject to Executive's employment with the
Company through the end of the relevant evaluation period. Executive's bonus
shall be reviewed annually by the Compensation Committee of the Board for
possible increases in light of Executive's performance and competitive data.

          (c)  Equity Compensation.

               (i)  Stock Options. Executive has received certain past grants of
stock options and will be eligible to receive such future grants as are approved
by the Board in accordance with the Company's employee stock option plan.

          (d)  Severance.

               (i)  Voluntary Termination for Good Reason; Involuntary
Termination Other Than for Cause. If Executive's employment with the Company is
voluntarily terminated by Executive for Good Reason (as defined below) or is
involuntarily terminated by the Company other than for Cause (as defined below),
then, subject to Executive executing and not revoking a standard form of mutual
release of claims with the Company (i) Executive shall receive continued
payments of one year's Base Salary, less applicable withholding, in accordance
with the Company's standard payroll practices, (ii) all of Executive's then
outstanding options to purchase shares of Company common stock shall become
fully vested and exercisable, and/or the restrictions applicable to unvested
shares of common stock purchased by Executive upon exercise of options to
purchase shares of Company common stock shall lapse, immediately prior to the
date

                                       2
<PAGE>   3

of Executive's termination of employment, (iii) the Company shall pay the group
health, dental and vision plan continuation coverage premiums for Executive and,
if relevant, his covered dependents under Title X of the Consolidated Budget
Reconciliation Act of 1985, as amended ("COBRA") for the lesser of (A) twelve
(12) months from the date of Executive's termination of employment, or (B) the
date upon which Executive and his covered dependents are covered by similar
plans of Executive's new employer and (iv) the Company shall reimburse Executive
for the costs of relocation, if any, of Executive; provided, however that such
reimbursement shall not exceed the relocation benefits paid to Executive in
connection with his initial commencement of employment with the Company.

     For the purposes of this Agreement, "Cause" means (i) a material act of
dishonesty made by Executive in connection with Executive's responsibilities as
an employee, (ii) Executive's conviction of, or plea of nolo contendere to, a
felony, (iii) Executive's gross misconduct in connection with the performance of
his duties hereunder or (iv) Executive's material breach of his obligations
under this Agreement; provided, however, that with respect to clauses (iii) and
(iv), such actions shall not constitute Cause if they are cured by Executive
within thirty (30) days following delivery to Executive of a written explanation
specifying the basis for the Company's beliefs with respect to such clauses.

     For the purposes of this Agreement, "Good Reason" means (i) a reduction in
Executive's Base Salary, (ii) a reduction in Executive's title (whether or not
material) or a material reduction in Executive's authority or duties, (iii) the
requirement that Executive relocate from his current place of residence or that
the company headquarters relocate more than 15 miles from its current location,
or (iv) the Company's material breach of its obligations under this Agreement;
provided, however, that with respect to clause (iv), such material breach shall
not provide a basis for termination for Good Reason if it is cured by the
Company within thirty (30) days following delivery to the Company of a written
explanation specifying the basis for the Executive's beliefs with respect to
such clause.

     The Executive shall not be required to mitigate the value of any severance
benefits contemplated by Section 4 of this Agreement, nor shall any such
benefits be reduced by any earnings or benefits that the Executive may receive
from any other source.

     5.   Total Disability of Executive. If Executive becomes permanently and
totally disabled (as defined in accordance with Internal Revenue Code Section
22(e)(3) or its successor provision) during the term of this Agreement,
employment hereunder shall automatically terminate and Executive shall be
treated as having been terminated other than for Cause for purposes of Section 4
of this Agreement.

                                       3
<PAGE>   4

     6.   Death of Executive. If Executive dies while employed by the Company
pursuant to this Agreement, Executive shall be treated as having been terminated
other than for Cause for purposes of Section 4 of this Agreement.

     7.   Assignment. This Agreement shall be binding upon and inure to the
benefit of (a) the heirs, beneficiaries, executors and legal representatives of
Executive upon Executive's death and (b) any successor of the Company. Any such
successor of the Company shall be deemed substituted for the Company under the
terms of this Agreement for all purposes. As used herein, successor shall
include any person, firm, corporation or other business entity which at any
time, whether by purchase, merger or otherwise, directly or indirectly acquires
all or substantially all of the assets or business of the Company. None of the
rights of Executive to receive any form of compensation payable pursuant to this
Agreement shall be assignable or transferable except through a testamentary
disposition or by the laws of descent and distribution upon the death of
Executive. Any attempted assignment, transfer, conveyance or other disposition
(other than as aforesaid) of any interest in the rights of Executive to receive
any form of compensation hereunder shall be null and void.

     8.   Notices. All notices, requests, demands and other communications
called for hereunder shall be in writing and shall be deemed given if (i)
delivered personally or by facsimile, (ii) one (1) day after being sent by
Federal Express or a similar commercial overnight service, or (iii) three (3)
days after being mailed by registered or certified mail, return receipt
requested, prepaid and addressed to the parties or their successors in interest
at the following addresses, or at such other addresses as the parties may
designate by written notice in the manner aforesaid:

                        If to the Company:
                        Attn: Chief Financial Officer
                        diaDexus, Inc.
                        3303 Octavius Drive
                        Santa Clara, CA 95054

                        If to Executive:
                        Patrick Plewman
                        San Jose, CA 95138
                        Tel:
                        Fax:

                        Or at the last residential address known by the Company.

                                       4
<PAGE>   5

     9.   Severability. In the event that any provision hereof becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or
void, this Agreement shall continue in full force and effect without said
provision.

     10.  Proprietary Information Agreement. Executive has entered into the
Company's standard Employee Proprietary Information Agreement (the "Proprietary
Information Agreement") upon commencing employment hereunder.

     11.  Entire Agreement. This Agreement, the indemnification agreement and
employee benefit plans referred to in Section 2 and the Proprietary Information
Agreement represent the entire agreement and understanding between the Company
and Executive concerning Executive's employment relationship with the Company,
and supersede and replace any and all prior agreements and understandings
concerning Executive's employment relationship with the Company.

     12.  Non-Binding Mediation, Arbitration and Equitable Relief.

          (a)  The parties agree to make a good faith attempt to resolve any
dispute or claim arising out of or related to this Agreement through
negotiation. In the event that any dispute or claim arising out of or related to
this Agreement is not settled by the parties hereto, the parties will attempt in
good faith to resolve such dispute or claim by non-binding mediation in Santa
Clara County, California to be conducted by one mediator belonging to the
American Arbitration Association. The mediation shall be held within thirty (30)
days of the request therefor. The costs of the mediation shall be borne equally
by the parties to the mediation.

          (b)  Except as provided in Section 12(e) below, Executive and the
Company agree that, to the extent permitted by law, any dispute or controversy
arising out of, relating to, or in connection with this Agreement, or the
interpretation, validity, construction, performance, breach, or termination
thereof which has not been resolved by negotiation or mediation as set forth in
Section 12(a) shall be finally settled by binding arbitration to be held in
Santa Clara County, California, in accordance with the National Rules for the
Resolution of Employment Disputes then in effect of the American Arbitration
Association (the "Rules"). The arbitrator may grant injunctions or other relief
in such dispute or controversy. The decision of the arbitrator shall be
confidential, final, conclusive and binding on the parties to the arbitration.
Judgment may be entered under a protective order on the arbitrator's decision in
any court having jurisdiction.

          (c)  The arbitrator shall apply California law to the merits of any
dispute or claim, without reference to rules of conflict of law. The arbitration
proceedings shall be governed by federal arbitration law and by the Rules,
without reference to state arbitration law. Executive hereby expressly consents
to the personal jurisdiction of the state and federal courts located in

                                       5
<PAGE>   6

California for any action or proceeding arising from or relating to this
Agreement and/or relating to any arbitration in which the parties are
participants.

          (d)  Executive understands that nothing in Section 12 modifies
Executive's at-will status. Either the Company or Executive can terminate the
employment relationship at any time, with or without cause.

          (e)  EXECUTIVE HAS READ AND UNDERSTANDS SECTION 12, WHICH DISCUSSES
ARBITRATION. EXECUTIVE UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, EXECUTIVE
AGREES, TO THE EXTENT PERMITTED BY LAW, TO SUBMIT ANY FUTURE CLAIMS ARISING OUT
OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT, OR THE INTERPRETATION,
VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH, OR TERMINATION THEREOF TO BINDING
ARBITRATION, AND THAT THIS ARBITRATION CLAUSE CONSTITUTES A WAIVER OF
EXECUTIVE'S RIGHT TO A JURY TRIAL AND RELATES TO THE RESOLUTION OF ALL DISPUTES
RELATING TO ALL ASPECTS OF THE EMPLOYER/EXECUTIVE RELATIONSHIP, INCLUDING BUT
NOT LIMITED TO, THE FOLLOWING CLAIMS:

               (i)  ANY AND ALL CLAIMS FOR WRONGFUL DISCHARGE OF EMPLOYMENT;
BREACH OF CONTRACT, BOTH EXPRESS AND IMPLIED; BREACH OF THE COVENANT OF GOOD
FAITH AND FAIR DEALING, BOTH EXPRESS AND IMPLIED; NEGLIGENT OR INTENTIONAL
INFLICTION OF EMOTIONAL DISTRESS; NEGLIGENT OR INTENTIONAL MISREPRESENTATION;
NEGLIGENT OR INTENTIONAL INTERFERENCE WITH CONTRACT OR PROSPECTIVE ECONOMIC
ADVANTAGE; AND DEFAMATION.

               (ii) ANY AND ALL CLAIMS FOR VIOLATION OF ANY FEDERAL STATE OR
MUNICIPAL STATUTE, INCLUDING, BUT NOT LIMITED TO, TITLE VII OF THE CIVIL RIGHTS
ACT OF 1964, THE CIVIL RIGHTS ACT OF 1991, THE AGE DISCRIMINATION IN EMPLOYMENT
ACT OF 1967, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE FAIR LABOR
STANDARDS ACT, THE CALIFORNIA FAIR EMPLOYMENT AND HOUSING ACT, AND LABOR CODE
SECTION 201, et seq;

               (iii) ANY AND ALL CLAIMS ARISING OUT OF ANY OTHER LAWS AND
REGULATIONS RELATING TO EMPLOYMENT OR EMPLOYMENT DISCRIMINATION.

     13.  No Oral Modification, Cancellation or Discharge. This Agreement may
only be amended, canceled or discharged in writing signed by the parties hereto.

                                       6
<PAGE>   7

     14.  Withholding. The Company shall be entitled to withhold, or cause to be
withheld, from payment any amount of withholding taxes required by law with
respect to payments made to Executive in connection with his employment
hereunder.

     15.  Governing Law. This Agreement shall be governed by the laws of the
State of California.

     16.  Acknowledgment. Executive acknowledges that he has had the opportunity
to discuss this matter with and obtain advice from his private attorney, has had
sufficient time to, and has carefully read and fully understands all the
provisions of this Agreement, and is knowingly and voluntarily entering into
this Agreement.

                                       7

<PAGE>   8

     IN WITNESS WHEREOF, the undersigned have executed this Agreement:

/s/ SHARON TETLOW                           November 17, 2000
-----------------------------               -----------------------------
(Name)                                      Date
diaDexus, Inc.

/s/ PATRICK PLEWMAN                         November 17, 2000
-----------------------------               -----------------------------
Patrick Plewman                             Date
Executive

                                       8<PAGE>   1
                                                                   EXHIBIT 10.17

                             CONFIDENTIAL TREATMENT                REDACTED FOR
                                   REQUESTED                     CONFIDENTIALITY

               The asterisked portions of this document have been
            omitted and are filed separately with the Securities and
                              Exchange Commission

                      COLLABORATION AND LICENSE AGREEMENT

                               between and among

            SMITHKLINE BEECHAM plc, SMITHKLINE BEECHAM corp, INCYTE

                    PHARMACEUTICALS, INC. and DIADEXUS, LLC

1.   DEFINITIONS ..............................................................3

2.   DiaDexus STRUCTURE ......................................................15

3.   INCYTE ..................................................................15

4.   SB ......................................................................20

5.   DiaDexus.................................................................24

6.   ROYALTIES/MILESTONES/OTHER PAYMENTS .....................................33

7.   THIRD PARTY AGREEMENTS ..................................................39

8.   BIOINFORMATICS COMMITTEE ................................................40

9.   INFORMATION EXCHANGE ....................................................40

10.  RESEARCH COMMITTEE ......................................................45

11.  RESEARCH PLAN ...........................................................45

12.  CONFIDENTIALITY .........................................................45

13.  DILIGENCE ...............................................................48

14.  PATENT PROSECUTION AND LITIGATION .......................................51

15.  STATEMENTS AND REMITTANCES ..............................................53

16.  TERM: TERMINATION .......................................................54

17.  REPRESENTATIONS AND WARRANTIES; COVENANTS ...............................55

18.  INDEMNITY ...............................................................57

19.  MISCELLANEOUS PROVISIONS ................................................59

     SIGNATURE PAGE ..........................................................64

     APPENDICES

                                       2
<PAGE>   2
                      COLLABORATION AND LICENSE AGREEMENT

     This Collaboration and License Agreement, made as of the 2nd day of
September 1997, by and among SmithKline Beecham Corporation, a Pennsylvania
corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania
corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania
19101, U.S.A.; SmithKline Beecham plc, an English corporation with its
principal offices at New Horizons Court, Brentford, Middlesex, TW8 9EP,
England; Incyte Pharmaceuticals, Inc., a Delaware corporation with offices at
3174 Porter Drive, Palo Alto, California 94304; and diaDexus, a Delaware
limited liability company with offices at 3233 Scott Boulevard Suite 102, Santa
Clara, California 95054;

                                  WITNESSETH:

     WHEREAS, Incyte and SB have developed intellectual property with respect
to certain high throughput genomic DNA sequencing and bioinformatics analysis
technologies and to certain DNAs and to proteins they encode;

     WHEREAS, Incyte and SB have established DiaDexus for the purpose of
undertaking the research, development and commercialization of certain
diagnostic products;

     WHEREAS, Incyte and SB desire to provide technical and financial
assistance to DiaDexus in connection with the research, development and
commercialization of certain diagnostic products, as set forth below;

     WHEREAS, Incyte, SB, and DiaDexus desire to grant to each other certain
rights relating to the research, development and commercialization of certain
diagnostic and other products, as set forth below;

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
herein contained, the parties hereto agree as follows:

                                1.0  DEFINITIONS

"Affiliate(s)": shall mean individually and collectively Incyte Affiliates,
DiaDexus Affiliates, and SB Affiliates. For the purposes of this Agreement,
DiaDexus shall not be an Affiliate of either SB or Incyte.

"Bioinformatics": shall mean computer software and know-how each useful for the
analysis, comparison, and curation of nucleic acid and protein sequences, and

                                       3
<PAGE>   3
curation of information related to such sequences; and software for the
construction and maintenance of databases for the compilation of such sequences
and their associated information.

"cDx Homebrew(s)"("HB"): shall mean a Clinical Diagnostic performed as a
service by a service provider prior to commercial launch of an RA Approved Kit.

"cDx Kit(s)": shall mean an RA Approved Kit for use in performing a Clinical
Diagnostic.

"Class I Dx Test(s)": shall mean (a) a simultaneous analysis of protein or
peptide analytes representing no greater than twenty (20) Gene Product(s); (b)
analysis of any number of molecules other than proteins (or peptides) or
nucleic acids; and/or (c) nucleic acid probe based analysis performed and
visualized in situ within a cell or tissue to detect specific nucleic acid
sequence(s) representing no more than two (2) Gene Product(s); each of which is
tested for in a human tissue or other human biological sample.

"Class II Dx Test(s)": shall mean (a) simultaneous analysis of nucleic acid
analytes representing up to and including twenty (20) Gene Product(s) (or
single- or multi-based changes therein) which is not performed and visualized
in situ within a cell or tissue; and/or (b) nucleic acid probe based analysis
performed and visualized in situ within a cell or tissue to detect specific
nucleic acid sequences representing three (3) to twenty (20) Gene Product(s);
each of which is tested for in a human tissue or other human biological
sample. The results reported with respect to each such Gene Product included in
a Class II cDx Test must be required for the Test to be valid. More than one
Class II cDx Test may be performed simultaneously using the same reagent(s)
and/or device(s).

"Class III Dx Test(s)": shall mean (a) simultaneous analysis of nucleic acid
analytes representing greater than twenty (20) Gene Product(s) (or single- or
multi-base changes therein); and/or (b) simultaneous analysis of protein
analytes representing greater than twenty (20) Gene Product(s); each of which
is tested for in a human tissue or other human biological sample. The results
reported with respect to each such Gene Product included in a Class III cDx
Test must be required for the Test to be valid. More than one Class III cDx
Test may be performed simultaneously using the same reagent(s) and/or
device(s).

"Clinical Non-genomic DiaDexus Data": shall mean DiaDexus IP which is data
collected on an individual's health or disease status but excluding genomic
data such as DNA sequence analysis and mRNA expression analysis.

                                       4

<PAGE>   4
"Clinical Diagnostic(s)" ("cDx"): shall mean test(s) performed on a human tissue
or other human biological sample, the results of which are provided to payors,
providers, or patients for use in the clinical management of individual
patients, which become part of such patient's health record.

"DiaDexus": shall mean diaDexus, a Delaware limited liability company with
offices at 3233 Scott Boulevard Suite 102, Santa Clara CA; and any DiaDexus
Affiliate(s) thereof to which any rights and/or obligations shall be assigned
and/or delegated pursuant to this Agreement.

"DiaDexus Affiliate": shall mean any corporation, firm, partnership, or other
legal entity, which is directly or indirectly owned or under common ownership
by DiaDexus to the extent of which the common stock or other equity ownership
thereof is one hundred percent (100%) owned by DiaDexus; provided however, that
where local laws require a minimum percentage of local ownership, the status of
DiaDexus Affiliate will be established if DiaDexus directly or indirectly owns
or controls one hundred percent (100%) of the maximum ownership percentage that
may, under such local laws, be owned or controlled by foreign interests.

"DiaDexus IP": shall mean DiaDexus Know-How and DiaDexus Patents.

"DiaDexus Know-How": shall mean any and all data, substances, processes,
materials, formulae, know-how and inventions which are owned by DiaDexus or with
respect to which DiaDexus has a right to grant a license. DiaDexus Know-How
shall not include Incyte Diagnostic Know-How, SB Diagnostic Know-How, Incyte
Technology Know-How, or SB Technology Know-How.

"DiaDexus Patents": shall mean all patents and patent applications to the
extent they claim DiaDexus Know-How, which are owned by DiaDexus or to which
DiaDexus has the right to grant licenses. Included within the definition of
DiaDexus Patents are all continuations, continuations-in-part, divisions,
patents of addition, reissues, renewals, extensions, registrations,
confirmations, re-examinations thereof and any provisional applications and all
SPCs. DiaDexus Patents shall not include Incyte Diagnostic Patents, SB
Diagnostic Patents, Incyte Technology Patents, or SB Technology Patents.

"Effective Date": shall mean the date first written above.

"Extended License Period": shall mean the period from the Effective Date up to
and including eight (8) years thereafter.

                                       5
<PAGE>   5
"Gene Product(s)": shall mean a protein (including peptides and polypeptides) or
nucleic acid analyte representing or encoded by a single gene. Multiple alleiic
forms of a gene and/or multiple splice variants of a gene represent one Gene
Product.

"Healthcare Informatics Product" ("Healthcare-Lx Product(s)"): shall mean a
database product containing data selected by SB and Incyte which is provided on
a commercial basis to healthcare payors, providers, consumers, and/or
healthcare companies for the purpose of (a) making healthcare management or
healthcare delivery decisions for individual patients and healthcare consumers
and/or (b) analysis of healthcare resource utilization and allocation.

"HGS Agreements": shall mean the agreements listed on Appendix A.

"Homebrew Territory": shall mean the countries and territories in which a Party
or its Affiliates has an existing service and/or distribution presence to
feasibly conduct a cDx Homebrew at the time a first right to a license to such
cDx Homebrew is offered to it pursuant to this Agreement. Such cDx Homebrew
service or distribution presence in such country or territory may be indirect
so long as the Party also maintains a direct presence to perform cDx Homebrews
in a Major Market Country. The United States shall be included in the Homebrew
Territory if the relevant Party and/or its Fifty Percent Affiliate has a
service and distribution capability similar to, or competitive with, one of the
major United States clinical diagnostic service laboratories (e.g., SmithKline
Beecham Clinical Laboratories, LabCorp or Quest) to provide such Homebrew. In
the case of Incyte, such service and distribution capability may be accessed
via partnership with SB, as anticipated by Paragraph 3.5. Fifty Percent
Affiliate for the purposes of this Paragraph and Paragraph 7.1 shall mean any
corporation, firm, partnership or other entity, whether de jure or de facto,
which directly or indirectly owns, is owned by or is under common ownership
with a Party to the extent of at least fifty percent (50%) of the equity (or
such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction) having the power to vote on or direct
the affairs of the entity, and any person, firm, partnership, corporation or
other entity actually controlled by, controlling or under common control with a
Party.

"Incyte": shall mean Incyte Pharmaceuticals, Inc., a Delaware corporation with
offices at 3174 Porter Drive, Palo Alto, California 94304; and any Incyte
Affiliate(s) thereof to which any rights and/or obligations shall be assigned
and/or delegated pursuant to this Agreement.

"Incyte Affiliate": shall mean any corporation, firm, partnership, or other
legal entity, which is directly or indirectly owned or under common ownership
by Incyte to the extent of which the common stock or other equity ownership
thereof is one hundred percent (100%) owned by Incyte; provided however, that
where local laws

                                       6
<PAGE>   6

require a minimum percentage of local ownership, the status of Incyte Affiliate
will be established if Incyte directly or indirectly owns or controls one
hundred percent (100%) of the maximum ownership percentage that may, under such
local laws, be owned or controlled by foreign interests.

"Incyte Database Agreements": shall mean the Collaborative LifeSeq(R)
Agreement and the Collaborative PathoSeq(TM) Database Agreement each between
Incyte and DiaDexus relating to Incyte Database Products entered into
contemporaneously herewith.

"Incyte Database Know-How": shall have the same meaning as Database Know-how
and/or Microbial Database Know-How as defined in the Incyte Database
Agreement(s), collectively or singly as applicable.

"Incyte Database Technology": shall have the same meaning as Incyte Database
Technology and/or Incyte Technology as defined in the Incyte Database
Agreements, collectively or singly as applicable.

"Incyte Database Products": shall mean individually and collectively LifeSeq(R),
LifeSeq Atlas(TM), LifeSeq(R)-FL, LifeSeq Arrays(TM) and PathoSeq(TM) as well as
the LifeSeq Gene Album(TM) reagent set each as defined in the Incyte Database
Agreements.

"Incyte Diagnostic IP": shall mean individually and collectively Incyte
Diagnostic Know-How and Incyte Diagnostic Patents.

"Incyte Diagnostic Know-How": shall mean any and all data, substances,
processes, materials,  formulae, know-how and inventions with respect to a Gene
Product or set of Gene Product(s) derived from laboratory data resulting from a
prospective study which has been identified by Incyte as having utility as a
potential cDx Homebrew, cDx Kit, or Class I rDx Kit or Class I rDx Service using
standard biology laboratory techniques above and beyond bioinformatics analysis
of data, and is owned by Incyte or with respect to which Incyte has a right to
grant a license, consistent with the terms and conditions of this Agreement and
which are listed on Appendix B (which may be amended from time to time) or is
otherwise expressly provided to DiaDexus in writing by Incyte. Incyte Diagnostic
Know-How shall not include Incyte Database Technology.

"Incyte Diagnostic Patents": shall mean all patents and patent applications to
the extent they claim Incyte Diagnostic Know-How, which are owned by Incyte or
to which Incyte otherwise has the right to grant licenses consistent with the
terms and conditions of this Agreement. Included within the definition of
Incyte Diagnostic Patents, without limitation, are all continuations,
continuations-in-part, divisions,

                                       7
<PAGE>   7
patents of addition, reissues, renewals, extensions, registrations,
confirmations, re-examinations thereof and any provisional applications and all
SPCs. Incyte Diagnostics Patents are listed on Appendix C which may be amended
from time to time.

"Incyte IP": shall mean any and all data, substances, processes, materials,
formulae, know-how, patents, patent applications and inventions which are owned
by Incyte or with respect to which Incyte has a right to grant a license
including, but not limited to, all rights under Incyte's database products.
Incyte IP shall not include Incyte Diagnostic IP and Incyte Technology IP.

"Incyte Rx Product": shall mean an Rx Product sold by Incyte or its licensees
of such Rx Product.

"Incyte Technology Know-How": shall mean any and all data, substances,
processes, materials, formulae, know-how and inventions which may be useful for
Making, Having Made, Using, and/or Selling Clinical Diagnostic(s) which are
owned by Incyte or with respect to which Incyte has a right to grant a license
and which are listed on Appendix D (which may be amended from time to time) or
are otherwise expressly provided to DiaDexus in writing by Incyte. Incyte
Technology Know-How includes Bioinformatics, and results of bioinformatics
analysis such as array designs and data mining, and array technology but does
not include Incyte Diagnostic Know-How or Incyte Database Technology.

"Incyte Technology IP": shall mean individually and collectively Incyte
Technology Know-How and Incyte Technology Patents.

"Incyte Technology Patents": shall mean all patents and patent applications to
the extent they claim Incyte Technology Know-How, which are owned by Incyte or
to which Incyte otherwise has the right to grant licenses. Included within the
definition of Incyte Technology Patents, without limitation, are all
continuations, continuations-in-part, divisions, patents of addition, reissues,
renewals, extensions, registrations, confirmations, re-examinations thereof and
any provisional applications and all SPCs. Incyte Technology Patents are listed
on Appendix D which may be amended from time to time.

"IND": shall mean a claimed investigational exemption for a new drug filed with
the United States Food and Drug Administration (FDA) or its successor or its
equivalent in a Major Market.

"Initial License Period": shall mean the period beginning on the Effective Date
and ending four (4) years thereafter.

                                       8
<PAGE>   8
"Investigational Trials Informatics Product(s)" ("Investigational-Ix
Product(s)"): shall mean a database product containing and useful for the
analysis of clinical data or data derived from human tissue or other human
biological samples including but not limited to gene expression and/or DNA
sequence information and/or results of Tests, each derived from human patients
selected on the basis of a disease process or a treatment protocol common to all
such patients (along with relevant clinical controls or comparators), which
database is designed for the purpose of determining significance of such
information in that disease process or treatment setting.

"Ix Products": shall mean Investigational-Ix Products, Healthcare-Ix Products,
and Research-Ix Products.

"Kit": shall mean a specific set of reagents and devices, and possibly also
including software and consumable labware, all of which together are sold or
otherwise provided on a commercial basis to an end user for the conduct of a
specific test.

"Licensing Revenues" shall mean, with respect to a license granted by Incyte or
SB in accordance with Paragraph 6.1(f), as the case may be:

        (a)     All licensing revenues received by Incyte or SB, as the case may
be, from Third Parties solely in consideration of a license to such DiaDexus
Patent or reasonably apportioned thereto; and which are received by Incyte or
SB, as the case may be, in excess of any revenues received for Incyte IP or SB
IP, as the case may be, in the absence of such DiaDexus Patents;

        (b)     Licensing Revenues shall include non-cash payments received by
Incyte or SB, as the case may be, from Third Parties solely in consideration of
a license to such DiaDexus Patents (including any DiaDexus Patents assigned to
Incyte pursuant to the Incyte Database Agreements) or reasonably apportioned
thereto. Licensing Revenues shall also include consideration received by Incyte
or SB, as the case may be, with respect to an assignment or other conveyance by
Incyte or SB as the case may be of its ownership interests in any DiaDexus
Patent to a Third Party. The cash value of such non-cash payments shall be
determined in good faith by Incyte or SB as the case may be, and shall be
reflected in financial statements prepared on a basis consistent with generally
accepted accounting principles.

        (c)     Licensing Revenues specifically excludes:

                (i)     research and development funding, equity investments,
database subscription fees, satellite database fees, fees related to Incyte
intellectual property or SB intellectual property (other than any DiaDexus
Patents assigned to Incyte pursuant to the Incyte Database Agreements) as the
case may be and other fees

                                       9
<PAGE>   9
under Incyte's database agreements, each unrelated to a separate license to a
DiaDexus Patent; and

          (ii) any royalties, payments (cash or non-cash) or other compensation
made to SB under the HGS Agreements.

"Make, Have Made, Use, and Sell (Making, Having Made, Using, and Selling)":
shall mean all exclusionary rights now or in the future conferred by a patent
or equivalent of a patent (e.g., a SPC), copyright, or trade secret law of each
applicable respective jurisdiction of the world, including but not limited to
the right to practice, make, have made, use, offer to sell, sell, import, copy,
display, license, and distribute.

"Major Market": shall mean the United States, United Kingdom, Germany, France,
Italy, Spain, Switzerland, or Japan.

"Net Ix Revenue": shall mean the revenues received in consideration for the
licenses of an Ix Product by Incyte or SB as the case may be (the Selling
Party), less any of the following charges or expenses, to the extent each is
actually incurred (and not otherwise recovered) and does not exceed the
reasonable and customary amount for such item in the market in which such
license occurred:

     (a)  credits, allowances and rebates to, and chargebacks from the account
of, such customers for damaged or returned Ix Product;

     (b)  actual freight and insurance costs incurred by the Selling Party in
transporting the Ix Product to such customers;

     (c)  trade discounts, cash discounts, quantity discounts, rebates and
other price reduction programs;

     (d)  sales, value-added and other direct taxes paid by the Selling Party;

     (e)  customs duties, surcharges and other governmental charges incurred in
connection with the exportation or importation of the Ix Product;

     (f)  any other similar, reasonable and customary deductions paid or
incurred by the Selling Party which are appropriately deducted from revenues.

     If the Ix Product is licensed in combination with other Product(s), the
Net Ix Revenues attributable to the Ix Product shall be determined by prorating
the revenues received from the combination products according to the fees or
values established by the Selling Party for the separate Product(s) contained
in the

                                       10

<PAGE>   10
combination product, whether or not such Product(s) are licensed separately,
provided that such fees or values are reasonably related to the fee or value
potentials of the separate Product(s) and are consistent with fees customarily
charged in the industry for comparable products.

"Net Sales": shall mean the gross invoiced sales of a Product by SB or Incyte
or their Affiliates or sublicensees as the case may be ("the Selling Party") to
Third Parties:

     (a)  in finished product form (i.e., packaged and labeled for sale to the
ultimate consumer); or

     (b)  in final stage bulk material form with respect to those products sold
in a country which is not a Major Market and where local country legal or
governmental requirements as reasonably determined by the Selling Party,
stipulate that such product be in a form other than finished product form (such
as final stage bulk material ready for conversion to final form, or bulk
tablets, bulk capsules, bulk ampoules or bulk vials) to distributors who
subsequently convert such product into finished product form and sell to Third
Parties, provided that such distributors shall not be considered sublicensees
for purposes of this Net Sales definition;

less deductions actually allowed or specifically allocated and actually
incurred to Product by the Selling Party using generally accepted accounting
standards and reasonable practices with respect to sales of all of such party's
products, consistently applied, for the following:

     (i)   transportation charges, including insurance, for transporting
Product;

     (ii)  sales and excise taxes and duties paid or allowed by the Selling
Party and any other governmental charges imposed upon the production,
importation, use or sale of such Product and paid by the Selling Party;

     (iii) trade, quantity and cash discounts actually allowed on Product;

     (iv)  allowances or credits to customers on account of rejection or return
of Product in accordance with SB's or Incyte's (or their sublicensees) returned
goods policy or on account of retroactive price reductions affecting such
Product; and

     (v)   Product rebates and Product charge backs including those granted to
managed care entities (including Medicaid rebates).

Any accruals for the foregoing deductions shall be reconciled with actual
results on a quarterly basis and any adjustments shall be reflected in the
subsequent quarter's computation of Net Sales.

Sales between a Selling Party and its sublicensees (other than sublicensees
that are end-users) shall be excluded from the computation of Net Sales and no
royalties will be payable on such sales.

Notwithstanding the immediately preceding sentence, it is understood that any
transactions with respect to an Rx Product between a Selling Party or any of
its or

                                       11

<PAGE>   11

their Affiliates or sublicensees on the one hand and a PSB on the other hand
shall be on an arms length basis. In the event that any PSB type activity is
within a Party or within any of its Affiliates or its or their sublicensees as
only part of its or their total activities rather than in a separate Affiliate,
a notional Net Sales figure will be calculated on an arms length basis to cover
such activities, in any event not less than the weighted average net sales
price to unaffiliated Third Parties in the same country. The term "PSB" as used
in this definition shall mean any present or future Affiliate of a Party or its
sublicensees which conducts a pharmaceutical service business for or on behalf
of Third Parties, including pharmaceutical benefits management services
(hereinafter "PBM"), wholesaler distribution, pharmacy distribution,
managed-care services, disease-management services, hospital services, or
mail-order prescription pharmacy services. As of the Effective Date, Affiliates
of SB which are included within the definition of PBM are Diversified
Pharmaceutical Services and Diversified Prescription Delivery LLC.

"Operating Agreement": shall mean the Operating Agreement for DiaDexus between
and among SB Corp, Incyte, and DiaDexus entered into of even date herewith.

"Party(ies)": shall mean individually and collectively SB, Incyte, and DiaDexus.

"Phase III Initiation": shall mean the date the first patient is dosed with an
Rx Product by or on behalf of Incyte or SB or their licensees, as the case may
be, in the first phase III clinical trial required for the filing of a new drug
application with the RA for such Rx Product.

"Product(s)": shall mean individually and collectively Tests and Rx Products.

"RA Approved Kit(s)": shall mean a Kit wherein the Regulatory Authority in the
relevant country or territory has granted Regulatory Approval for such Kit for
cDx use, or, in countries and territories where a Kit may be sold for cDx use
without such approval, such Kit is clinically validated to an extent similar to
that which would have been required by a Regulatory Authority in a country or
territory where such approval is required.

"rDx Kit(s)": shall mean any Kit for performing a test on a tissue or
biological sample which test is being conducted as a Research Diagnostic.

"Regulatory Approval": shall mean all the government approvals required to
market a product in a given country, including, but not limited to, product
registration(s) and price and marketing approval(s), as applicable, in such
country.

"Regulatory Authority (RA)": shall mean the FDA or the analogous regulatory
body of any other country or territory where a Test is performed or sold.

                                       12
<PAGE>   12
"Research Diagnostic(s)" ("rDx"): shall mean test(s) performed on a commercial
basis on a tissue or other biological sample, the results of which are provided
to any party for any purpose, excluding use as a Clinical Diagnostic.

"Research Diagnostics Service(s)" ("rDx Service(s)"): shall mean a Research
Diagnostic performed as a service.

"Research Informatics Product(s)" ("Research-Ix Product(s)"): shall mean any
database product which is used for any purpose other than as a Investigational
Trials Informatics Product or Healthcare Informatics Product.

"Research Plan": shall mean a research plan for a Test filed by DiaDexus
pursuant to Paragraph 11.1. Appendix F is a Research Plan form.

"Rx/Other": shall mean the field including any products or processes which are
not Tests or Ix Products.

"Rx Product": shall mean a product or service in the field of Rx/Other for the
prevention or treatment of any disease, state or condition by any means in
human or animals, which product was materially based on or materially derived
by SB's or Incyte's, as the case may be, use of DiaDexus IP as licensed under
this Agreement, and which are not Tests or Ix Products.

"SB": shall mean, individually and collectively, SmithKline Beecham
Corporation; SmithKline Beecham plc; and any SB Affiliate(s) to which any
rights and/or obligations of either of them shall be assigned and/or delegated
pursuant to this Agreement.

"SB Affiliate": shall mean any corporation, firm, partnership or other entity,
whether de jure or de facto, which directly or indirectly owns, is owned by or
is under common ownership with SB to the extent of at least fifty percent (50%)
of the equity (or such lesser percentage which is the maximum allowed to be
owned by a foreign corporation in a particular jurisdiction) having the power
to vote on or direct the affairs of the entity, and any person, firm,
partnership, corporation or other entity actually controlled by, controlling or
under common control with SB.

"SB Diagnostic IP": shall mean individually or collectively SB Diagnostic
Know-How and SB Diagnostic Patents.

"SB Diagnostic Know-How": shall mean any and all data, substances, processes,
materials, formulae, know-how and inventions with respect to a Gene Product
or set of Gene Product(s) having potential utility as a diagnostic product
which is a cDx

                                       13
<PAGE>   13
Homebrew, cDx Kit, or Class I rDx Service or Class I rDx Kit, owned by SB or
with respect to which SB has a right to grant a license consistent with the
terms and conditions of this Agreement and which are listed on Appendix G (which
may be amended from time to time) or is otherwise expressly provided to DiaDexus
in writing by SB.

"SB Diagnostic Patents": shall mean all patents and patent applications to the
extent they claim SB Diagnostic Know-How, which are owned by SB or to which SB
otherwise has the right to grant licenses consistent with the terms and
conditions of this Agreement. Included within the definition of SB Diagnostic
Patents, without limitation, are all continuations, continuations-in-part,
divisions, patents of addition, reissues, renewals, extensions, registrations,
confirmations, re-examinations thereof and any provisional applications and all
SPCs. SB Diagnostic Patents are listed on Appendix H which may be amended from
time to time.

"SB IP": shall mean any and all data, substances, processes, materials,
formulae, know-how, patents, and inventions which are owned by SB or with
respect to which SB has a right to grant a license but shall not include SB
Diagnostic IP and SB Technology IP.

"SB Rx Product": shall mean an Rx Product sold by SB or its licensees of such
Rx Product.

"SB Technology IP": shall mean individually and collectively SB Technology
Know-How and SB Technology Patents.

"SB Technology Know-How": shall mean any and all data, substances, processes,
materials, formulae, know-how and inventions which may be useful for Making,
Having Made, Using, and/or Selling Clinical Diagnostic(s) which are owned by SB
or with respect to which SB has a right to grant a license and which are listed
on Appendix I (which may be amended from time to time) or are otherwise
expressly provided to DiaDexus in writing by SB. SB Technology Know-How includes
Bioinformatics, and results of bioinformatics analysis such as array designs and
data mining, and array technology but does not include SB Diagnostic Know-How.

"SB Technology Patents": shall mean all patents and patent applications to the
extent they claim SB Technology Know-How, which are owned by SB or to which SB
otherwise has the right to grant licenses. Included within the definition of SB
Technology Patents, without limitation, are all continuations,
continuations-in-part, divisions, patents of addition, reissues, renewals,
extensions, registrations, confirmations, re-examinations thereof and any
provisional applications and all SPCs. SB Technology Patents are listed on
Appendix J which may be amended from time to time.

                                       14
<PAGE>   14
"SPC": shall mean a right based upon a patent to exclude others from making,
using or selling a product, such as a supplementary protection certificate.

"Test": shall mean individually or collectively a cDx Kit, cDx Homebrew, rDx
Kit, and rDx Service, as applicable.

"Third Party(ies)": means any individual or entity other than SB, Incyte or
DiaDexus.

"Valid Claim" shall mean a claim of an SB Diagnostic Patent, SB Technology
Patent, Incyte Diagnostic Patent, Incyte Technology Patent, or DiaDexus Patent,
as the case may be, which has not been held invalid or unenforceable by final
decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which is not
admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise.

                                  2.0 DiaDexus

2.1  SB and Incyte agree to form DiaDexus pursuant to the Operating Agreement
by and among SB Corp., Incite, and DiaDexus entered into as of even date
herewith.

                                   3.0 Incyte

3.1  General Provisions

     3.1.1  Unless expressly granted to DiaDexus pursuant to the terms and
     conditions of this Agreement and/or Incyte Database Agreements, Incyte
     retains all rights to Incyte Diagnostic IP and Incyte Technology IP.

     3.1.2  Notwithstanding any grants conveyed by Incyte under Incyte
     Diagnostic IP and Incyte Technology IP, Incyte retains the right to use
     such Incyte Diagnostic IP and Incyte Technology IP for its own internal
     research purposes.

     3.1.3  Notwithstanding anything else to the contrary, Incyte does not grant
     SB any rights pursuant to this Agreement under Incyte IP, Incyte Technology
     IP, or Incyte Diagnostic IP.

     3.1.4  Incyte retains all rights and does not grant DiaDexus any rights
     under Incyte IP under this Agreement.
<PAGE>   15

     3.2  Incyte Class I cDx Test(s) Diagnostic IP Grants and Incyte Technology
          IP Grants: Subject to all the terms and conditions of this Agreement,
          Incyte hereby grants the following rights in the field of Class I Dx
          Test(s);

          3.2.1 cDx Homebrew

               (a)  During the Initial License Period, Incyte grants DiaDexus
               an exclusive, world-wide, license under Incyte Diagnostic IP,
               with the right to sublicense pursuant to Paragraph 3.7, to
               Make, Have Made, Use, and Sell cDx Homebrews in the field of
               Class I Dx Test(s).

               (b) After the Initial License Period, Incyte grants DiaDexus an
               exclusive, world-wide, license under Incyte Diagnostic IP, with
               the right to sublicense pursuant to Paragraph 3.7, to Make,
               Have Made, Use, and Sell cDx Homebrews in the field of Class I
               Dx Test(s) with respect to cDx Homebrews for which DiaDexus has
               filed a Research Plan pursuant to Section 11.

          3.2.2 cDx Kit(s)

               (a) During the Initial License Period, Incyte grants DiaDexus an
               exclusive, world-wide license under Incyte Diagnostic IP, with
               the right to sublicense pursuant to Paragraph 3.7, to Make,
               Have Made, Use, and Sell cDx Kit(s) in the field of Class I Dx
               Test(s).

               (b) After the Initial License Period, Incyte grants DiaDexus an
               exclusive, world-wide license under Incyte Diagnostic IP, with
               the right to sublicense pursuant to Paragraph 3.7, to Make, Have
               Made, Use, and Sell cDx Kit(s) in the field of Class I Dx Test(s)
               with respect to cDx Kit(s) for which DiaDexus has filed a
               Research Plan pursuant to Section 11.

          3.2.3 rDx Kit(s) and rDx Service(s)

               (a) During the Initial License Period, Incyte grants DiaDexus a
               non-exclusive, world-wide license under Incyte Diagnostic IP,
               with the right to sublicense pursuant to Paragraph 3.7, to
               Make, Have Made, Use, and Sell rDx Kit(s) and rDx Service(s) in
               the field of Class I Dx Test(s); provided that with respect to
               nucleic acid based rDx Kit(s) and/or rDx Service(s), DiaDexus
               shall also be developing or selling the same nucleic acid based
               rDx Kit or rDx Service as a Class I cDx Kit or cDx Homebrew
               consistent with the grant to DiaDexus in Paragraphs 3.2.1 or
               3.2.2.

                                       16
<PAGE>   16
            (b)  After the Initial License Period, Incyte grants DiaDexus a
            non-exclusive, world-wide license under Incyte Diagnostic IP, with
            the right to sublicense pursuant to Paragraph 3.7, to Make, Have
            Made, Use, and Sell rDx Kit(s) and rDx Service(s) in the field of
            Class I Dx Test(s) with respect to rDx Kit(s) and rDx Service(s) for
            which DiaDexus has filed a Research Plan pursuant to Section 11,
            provided that with respect to nucleic acid based rDx Kit(s) and/or
            rDx Service(s), DiaDexus shall also be developing or selling the
            same nucleic acid based rDx Kit or rDx Service as a Class I cDx Kit
            or cDx Homebrew consistent with the grant to DiaDexus in Paragraphs
            3.2.1 or 3.2.2.

      3.2.4     Incyte Technology IP: All Class I Dx Test(s) and all Class II &
            III Dx Test(s) which are cDx Kit(s)

            (a)  For all Class I Dx Test(s) and all Class II & III Dx Test(s)
            which are cDx Kit(s), Incyte grants DiaDexus a non-exclusive,
            world-wide license under Incyte Technology IP provided to DiaDexus
            by Incyte during the Initial License Period to Make, Have Made, Use,
            and Sell such Tests. This license is sublicensable by DiaDexus
            pursuant to Paragraph 3.7 only on a Test by Test basis and only to
            the extent that such Incyte Technology IP is required for the
            conduct of the specific Test and further provided such Incyte
            Technology IP has been listed on Appendix D and/or E as being
            sublicenseable.

3.3.  Incyte Class II Dx Test(s) Grants: Subject to all the terms and conditions
      of this Agreement, Incyte hereby grants the following rights in the field
      of Class II DX Test(s);

      3.3.1     cDx Kit(s)

            (a)  During the Initial License Period, Incyte grants DiaDexus an
            exclusive, world-wide license under Incyte Diagnostic IP, with the
            right to sublicense pursuant to Paragraph 3.7, to Make, Have Made,
            Use, and Sell cDx Kit(s) in the field of Class II Dx Test(s).

            (b)  After the Initial License Period, Incyte grants DiaDexus an
            exclusive, world-wide license under Incyte Diagnostic IP, with the
            right to sublicense pursuant to Paragraph 3.7, to Make, Have Made,
            Use, and Sell cDx Kit(s) in the field of Class II DX Test(s) with
            respect to cDx Kit(s) for which DiaDexus has filed a Research Plan
            pursuant to Section 11.

      3.2.2     cDx Homebrew(s), rDx Kit(s), and rDx Service(s)

                                       17

<PAGE>   17
            (a)  Subject to DiaDexus's right to conduct research only in
            furtherance of the rights explicitly granted therein. Incyte retains
            all rights under Incyte Diagnostic IP and Incyte Technology IP to
            Make, Have Made, Use, and Sell cDx Homebrews, rDx Kit(s), and rDx
            Service(s) in the field of Class II Dx Test(s).

3.4   Incyte Class III Dx Test(s) Grants: Subject to all the terms and
      conditions of this Agreement, Incyte hereby grants the following rights in
      the Field of Class III Dx Test(s):

      3.4.1     cDx Kit(s)

            (a)  During the Initial License Period, Incyte grants DiaDexus an
            exclusive, world-wide license under Incyte Diagnostic IP, with the
            right to sublicense pursuant to Paragraph 3.7, to Make, Have Made,
            Use, and Sell cDx Kit(s) in the field of Class III Dx Test(s).

            (b)  After the Initial License Period, Incyte grants DiaDexus an
            exclusive, world-wide license under Incyte Diagnostic IP, with the
            right to sublicense, pursuant to Paragraph 3.7, to Make, Have Made,
            Use, and Sell cDx Kit(s) in the field of Class III Dx Test(s) with
            respect to cDx Kit(s) for which DiaDexus has filed a Research Plan
            pursuant to Section 11.

      3.4.2     cDx Homebrew, rDx-Kit(s), and rDx Service(s)

            (a)  Subject to DiaDexus's right to conduct research only in
            furtherance of the rights explicitly granted herein, Incyte retains
            all rights under Incyte Diagnostic IP and Incyte Technology IP to
            Make, Have Made, Use, and Sell cDx Homebrew(s), rDx-Kit(s) and rDx
            Service(s) in the field of Class III Dx Test(s).

3.5  Marketing Agreements

            (a)  Incyte grants SB a first right in the Homebrew Territory to
            enter into a marketing and/or distribution agreement with Incyte for
            any Class II or Class III Dx Tests being commercialized by Incyte
            which are cDx Homebrew(s) and for which Incyte, in its sole
            discretion, seeks a partner for product marketing and/or product
            distribution during the Initial License Period. Incyte agrees to
            notify SB in writing of such first right and agrees to extend to SB
            a six (6) month period in which to negotiate and execute such
            marketing and/or distribution agreement for such Tests. SB shall
            within thirty (30) days after receipt of such notice either accept
            in writing or decline such first right (no notice to Incyte within
            such thirty (30) day period shall constitute a waiver of such first
            right with respect to such Test). If SB accepts such first right in
            writing, SB and Incyte agree to negotiate exclusively with each
            other in good faith effort

                                       18

<PAGE>   18
    to execute such marketing and/or distribution agreement within such six (6)
    month period. In the event a marketing and/or distribution agreement is not
    entered into during such six (6) month period or a mutually agreed extension
    thereof, SB relinquishes any such first right with respect to such Test
    leaving Incyte free to pursue marketing and/or distribution agreements with
    Third Parties at its own discretion for such Test.

3.6     Bioinformatics

    3.6.1       During the Initial License Period, Incyte shall provide DiaDexus
        an opportunity to negotiate a commercial non-exclusive license for
        Bioinformatics of Incyte made commercially available by Incyte to Third
        Parties which Bioinformatics is not otherwise licensed pursuant to this
        Agreement or the Incyte Database Agreements.

    3.6.2       Except as otherwise expressly provided herein, DiaDexus has no
        rights to sublicense Bioinformatics rights it receives from Incyte under
        this Agreement or any agreement with Incyte without the prior express
        written permission of Incyte.

    3.6.3       It is the intent of Incyte, on a collaborative basis, to make
        certain Bioinformatics available to DiaDexus which is not otherwise
        available pursuant to Paragraph 3.6.1 (e.g., experimental bioinformatics
        tools etc.). However, the parties recognize that Incyte is under no
        obligation to provide (and may not have the rights to provide) such
        Bioinformatics to DiaDexus.

3.7     Sublicensing of Incyte Diagnostic IP and Incyte Technology IP: DiaDexus
        agrees that brokerage of Incyte Diagnostic IP or Incyte Technology IP is
        not permitted by DiaDexus nor in Incyte's best interests. Therefore:

    3.7.1       On an individual Test-by-Test basis, DiaDexus may sublicense to
        any Third Party the rights to such Test for which a Research Plan has
        been filed in accordance with Section 11 and the Incyte Diagnostic IP
        and/or Incyte Technology IP relating thereto, on an exclusive or
        non-exclusive basis, as the case may be, in order to Make, Have Made,
        Use, and Sell Tests as granted under this Section 3.0; provided,
        however, that without the prior express written consent of Incyte, no
        sublicense of Incyte Diagnostic IP or Incyte Technology IP will be
        granted to any Third Party in the absence of a corresponding license of
        rights to a given Test discovered, researched and/or developed by
        DiaDexus including the license of patent rights pertaining thereto owned
        by, licensed to or controlled by DiaDexus; and further provided that
        each sublicense has a grant which is consistent with the terms herein
        and DiaDexus shall be responsible for payments and royalties under

                                       19
<PAGE>   19
            such sublicenses due under Section 6.0 as if such were made by
            DiaDexus directly and pursuant to the terms and conditions of this
            Agreement.

     3.7.2  DiaDexus shall obtain the prior written commitment of any
            sublicensee to abide by all applicable terms and conditions of this
            Agreement. Promptly upon execution of any permitted sublicense under
            3.7.1, DiaDexus shall provide notice thereof to Incyte, and
            reasonable satisfactory evidence that such sublicense is in
            compliance with this Paragraph 3.7.

     3.7.3  Any purported sublicense in violation of this Section 3.7 shall be
            void.

3.8  Other Incyte agrees to negotiate with SB in good faith for access to Incyte
     Technology IP which is required for the commercially reasonable conduct of
     cDx Homebrews licensed to SB by DiaDexus pursuant to Section 5.

                                    4.0   SB
                                    --------

4.1  General Provisions

     4.1.1  Any SB Diagnostic IP which is based on the use of or derived from
            data or information obtained by SB pursuant to the HGS Agreements
            shall only be transferred to DiaDexus on a potential Test-by-
            potential Test basis and at DiaDexus's election pursuant to
            Paragraph 9.1.2. SB technology intellectual property based on the
            use of or derived from data or information obtained by SB pursuant
            to the HGS Agreements shall not be transferred to DiaDexus by SB.

     4.1.2  Unless expressly granted to DiaDexus pursuant to the terms and
            conditions of this Agreement, SB retains all rights to SB
            Diagnostic IP and SB Technology IP.

     4.1.3  Notwithstanding any grants conveyed by SB under SB Diagnostic IP
            and SB Technology IP, SB retains the right to use such SB
            Diagnostic IP and SB Technology IP for its own internal research
            purposes.

     4.1.4  Notwithstanding anything else to the contrary, SB retains all
            rights, and does not grant DiaDexus any rights under SB IP under
            this Agreement.

     4.1.5  Notwithstanding anything else to the contrary, SB does not grant
            Incyte any rights pursuant to this Agreement under SB IP, SB
            Technology IP, or SB Diagnostic IP.

                                       20
<PAGE>   20
4.2  SB cDx Homebrew Grants: Subject to all the terms and conditions of this
     Agreement, SB hereby grants the following rights to cDx Homebrew(s) in the
     field of Class I Dx Test(s), Class II Dx Test(s), and Class III Dx Test(s):

     4.2.1     cDx Homebrews

          (a)  During the Initial License Period SB grants DiaDexus an
          exclusive, world-wide license under SB Diagnostic IP with the right to
          sublicense pursuant to Paragraph 4.7, to Make, Have Made, Use, and
          Sell cDx Homebrews in the field of Class I Dx Test(s), Class II Dx
          Test(s), and Class III Dx Test(s).

          (b)  After the Initial License Period SB grants DiaDexus an exclusive,
          world-wide license under SB Diagnostic IP with the right to sublicense
          pursuant to Paragraph 4.7, to Make, Have Made, Use, and Sell cDx
          Homebrews in the field of Class I Dx Test(s), Class II Dx Test(s), and
          Class III Dx Test(s); provided DiaDexus has filed a Research Plan for
          such Homebrew pursuant to Section 11.

4.3  SB cDX Kit Grants: Subject to all the terms and conditions of this
     Agreement, SB hereby grants the following rights to cDx Kit(s) in the
     field of Class I Dx Test(s), Class II Dx Test(s), and Class III Dx Test(s):

     4.3.1     cDx Kit(s)

          (a)  During the Initial License Period, SB grants DiaDexus an
          exclusive, world-wide license under SB Diagnostic IP, with the right
          to sublicense pursuant to Paragraph 4.7, to Make, Have Made, Use, and
          Sell cDx Kit(s), in the field of Class I Dx Test(s), Class II Dx
          Test(s), and Class III Dx Test(s).

          (b)  After the Initial License Period, SB grants DiaDexus an
          exclusive, world-wide license under SB Diagnostic IP, with the right
          to sublicense pursuant to Paragraph 4.7, to Make, Have Made, Use, and
          Sell cDx Kit(s) in the field of Class I Dx Test(s), Class II Dx
          Test(s), and Class III Dx Test(s) with respect to cDx Kit(s) for
          which DiaDexus has filed a Research Plan pursuant to Section 11.

4.4  SB Class I Dx Test(s) which are rDx Service or rDx Kit(s) Grants: Subject
     to all the terms and conditions of this Agreement, SB hereby grants the
     following rights to rDx Service(s) and rDx Kit(s) in the field of Class I
     Dx Test(s):

                                       21

<PAGE>   21
      4.4.1       rDx Service(s) and rDx Kit(s)

            (a)   During the Initial License Period, SB grants DiaDexus a
            non-exclusive, world-wide license under SB Diagnostic IP, with the
            right to sublicense pursuant to Paragraph 4.7, to Make, Have Made,
            Use, and Sell rDx Service(s) and rDx Kit(s) in the field of Class I
            Dx Test(s).

            (b)   After the Initial License Period, SB grants DiaDexus a
            non-exclusive, world-wide license under SB Diagnostic IP, with the
            right to sublicense pursuant to Paragraph 4.7, to Make, Have Made,
            Use, and Sell rDx Service(s) and rDx Kit(s) in the field of Class I
            Dx Test(s) with respect to such rDx Service(s) and rDx Kit(s) for
            which DiaDexus has filed a Research Plan pursuant to Section 11.

            (c)   Subject to DiaDexus's right to conduct research only in
            furtherance of the rights explicitly granted herein, SB retains all
            rights under SB Diagnostic IP to Make, Have Made, Use, and Sell rDx
            Service(s) and rDx Kit(s) in the field of Class II and Class III Dx
            Test(s).

4.5   SB Technology IP grants: Subject to all the terms and conditions of this
      Agreement. SB hereby grants the following rights under SB Technology IP in
      the field of Class I Dx Test(s), Class II Dx Test(s), and Class III Dx
      Test(s):

      4.5.1       All Class I, Class II and Class III Dx Test(s)

            (a)   SB grants DiaDexus a non-exclusive, world-wide license under
            SB Technology IP provided to DiaDexus by SB during the Initial
            License Period, to Make, Have Made, Use, and Sell cDx Kit(s), cDx
            Homebrew(s), rDx Kit(s) and rDx Service(s) in the field of Class I
            Dx Test(s), Class II Dx Test(s), and Class III Dx Test(s). This
            license is sublicensable by DiaDexus pursuant to Paragraph 4.7 on a
            Test-by-Test basis and only to the extent such SB Technology IP is
            required for the conduct of the specific Test and further provided
            such SB Technology IP has been listed on Appendix I or J as being
            sublicenseable.

4.6   Bioinformatics/Ix Products:

      4.6.1       During the Initial License Period, SB shall provide DiaDexus
            an opportunity to negotiate a non-exclusive license for
            Bioinformatics of SB made commercially available by SB to Third
            Parties which Bioinformatics is not otherwise licensed pursuant to
            this Agreement.

                                       22
<PAGE>   22
4.6.2 Except as otherwise expressly provided herein, DiaDexus has no rights to
      sublicense Bioinformatics rights it receives from SB under this Agreement
      or any agreement with SB without the express written permission of SB.

4.6.3 It is the intent of SB, on a collaborative basis, to make certain
      Bioinformatics available to DiaDexus which is not otherwise available
      under subparagraph 4.6.1 (e.g., experimental bioinformatics tools, etc.).
      However, the parties recognize that SB is under no obligation to provide
      (and may not have the rights to provide) such Bioinformatics to DiaDexus.

4.6.4 SB grants Incyte a first right of offer to enter into an agreement with
      SB for commercialization of SB Bioinformatics platform(s) in the event SB,
      in its sole discretion, seeks to commercialize any SB Bioinformatics
      platform during the Initial License Period. If SB seeks to commercialize
      its Bioinformatics platform(s), SB agrees to provide Incyte promptly in
      writing with a description of each such Bioinformatics platform and the
      general terms of each such proposed agreement between Incyte and SB to
      commercialize such Bioinformatics platform. Incyte shall notify SB within
      sixty (60) days after receipt of such terms whether Incyte desires to
      proceed into negotiations with respect to each such commercialization
      agreement. If Incyte notifies SB in writing that it wishes to proceed, SB
      and Incyte agree to negotiate exclusively with each other in good faith to
      execute each such agreement within a period of one hundred eighty (180)
      days. In the event that Incyte declines in writing to proceed, or if the
      Parties cannot reach an agreement within the 180 day period, or a mutually
      agreed extension thereof, then during the Initial License Period, SB
      agrees not to enter into an agreement to commercialize any such
      Bioinformatics platform with any Third Party under more favorable terms
      and conditions than the terms and conditions last offered to Incyte unless
      such terms have been offered to Incyte in accordance with this Paragraph
      4.6.4.

4.6.5 DiaDexus hereby acknowledges that Incyte has ongoing research and
      development programs involving material investment by Incyte to produce
      and develop Incyte IP independent of that which would constitute Incyte
      Diagnostic IP, including Incyte IP which is or shall be provided to third
      parties on a non-exclusive commercial basis as Incyte database product(s),
      including Lx Product(s). Incyte shall provide SB and DiaDexus with access
      on commercial terms to those Ix Product(s), or other Incyte database
      products which are made generally available by Incyte to other Third
      Parties on a non-exclusive basis.

                                       23

<PAGE>   23
4.7  Sublicensing of SB Diagnostic IP and SB Technology IP: DiaDexus agrees that
     brokerage of SB Diagnostic IP or SB Technology IP is not permitted by
     DiaDexus nor is it in SB's best interests. Therefore:

     4.7.1     On an individual Test-by-Test basis, DiaDexus may sublicense to
               any Third Party the rights to such Test for which a Research Plan
               has been filed in accordance with Section 11 and the SB
               Diagnostic IP and/or SB Technology IP relating thereto, on an
               exclusive or non-exclusive basis, as the case may be, in order to
               Make, Have Made, Use, and Sell Tests as granted under this
               Section 4.0; provided, however, that without the prior express
               written consent of SB, no sublicense of SB Diagnostic IP or SB
               Technology IP will be granted to any Third Party in the absence
               of a corresponding license of rights to a given Test discovered,
               researched and/or developed by DiaDexus including the license of
               patent rights pertaining thereto owned by, licensed to or
               controlled by DiaDexus; and further provided that each sublicense
               has a grant which is consistent with the terms herein and
               DiaDexus shall be responsible for payments and royalties under
               such sublicenses due under Section 6.0 as if such were made by
               DiaDexus directly and pursuant to the terms and conditions of
               this Agreement.

     4.7.2     DiaDexus shall obtain the prior written commitment of any
               sublicensee to abide by all applicable terms and conditions of
               this Agreement. Promptly upon execution of any permitted
               sublicense under 4.7.1. DiaDexus shall provide notice thereof to
               SB, and reasonable satisfactory evidence that such sublicense is
               in compliance with this Paragraph 4.7.

     4.7.3     Any purported sublicense in violation of this Section 4.7 shall
               be void.

4.8  Tissue

     4.8.1     Consistent with the rights granted in this Section 4, SB shall
               provide DiaDexus with reasonable access to its tissue collections
               for its internal research purposes in the field of Class I Dx
               Test(s), Class II Dx Test(s) and Class III Dx Test(s). Such
               tissues are SB Technology Know-How.

4.9  Other: SB agrees to negotiate with Incyte in good faith for access to SB
     Technology IP which is required for the commercially reasonable conduct of
     rDx Service(s) licensed to Incyte by DiaDexus pursuant to Section 5.

                                      5.0    DiaDexus

                                       24
<PAGE>   24
5.1  General Provisions

     5.1.1     Notwithstanding any exclusive grants conveyed by DiaDexus under
               DiaDexus IP, DiaDexus retains the right to use such DiaDexus IP
               for its own internal research purposes.

     5.1.2     DiaDexus agrees not to intermingle any Incyte Database Know-How,
               Incyte Diagnostic Know-How, and/or Incyte Technology Know-How
               with any SB Diagnostic Know-How designated by SB as being based
               on or derived by its collaboration with HGS pursuant to Paragraph
               9.1.5.

     5.1.3     DiaDexus retains all rights under DiaDexus IP unless expressly
               granted to SB and/or Incyte pursuant to the terms and conditions
               of this Agreement.

     5.1.4     All rights and licenses granted by DiaDexus to SB and/or Incyte
               pursuant to Paragraphs 5.2, 5.3, and 5.4, shall include a
               non-exclusive sublicense or exclusive sublicense, as the case may
               be, by DiaDexus to any SB Diagnostic IP and/or Incyte Diagnostic
               IP each only as may be necessary to exercise such right or
               license. Such license shall only be granted exclusively hereunder
               to SB or Incyte, if such party had granted the license
               exclusively to DiaDexus in Section 3 or 4, as the case may be,
               and if not, such sublicense shall only be granted by DiaDexus to
               SB or Incyte pursuant to this Paragraph, as the case may be,
               non-exclusively.

5.2  DiaDexus Class I DX Test(s) Grants: Subject to all the terms and conditions
     of this Agreement, DiaDexus hereby grants the following rights to SB in the
     field of Class I DX Test(s):

     5.2.1     cDx Homebrew(s)

        (a)    DiaDexus grants SB a first right to negotiate with DiaDexus to
        obtain an exclusive license (with the right to sublicense) under
        DiaDexus IP, generated during the Extended License Period to Make, Have
        Made, Use, and Sell cDx Homebrew(s) in the field of Class I Dx Test(s)
        in the Homebrew Territory. Such license, if agreed to, would include a
        royalty and license fee as specified in Paragraph 6.3 and other terms
        and conditions mutually acceptable to the Parties and customary in such
        licenses, however, no additional payments beyond such royalty and
        license fee shall be required for such license.

        (b)    DiaDexus agrees to notify SB in writing of the commencement of
        such first right. SB and DiaDexus shall have a three (3) month period in

                                       25
<PAGE>   25
            which to negotiate and execute such license for such cDx Homebrew if
            the Parties mutually agree thereto. SB shall within thirty (30) days
            after receipt of such notice either accept in writing or decline
            such first right (no notice to DiaDexus within such thirty (30) day
            period shall constitute a waiver of such first right with respect to
            such cDx Homebrew). If SB accepts such first right in writing, SB
            and DiaDexus agree to negotiate exclusively with each other in good
            faith effort to reach mutually acceptable agreement and to execute
            such agreement within such three (3) month period. In the event a
            license agreement is not entered into during such three (3) month
            period or a mutually agreed extension thereof, SB shall have no
            further right with respect to such cDx Homebrew leaving DiaDexus
            free to pursue agreements with Third Parties or Incyte at its own
            discretion for such cDx Homebrew.

      5.2.2 rDx Services(s)

            (a)   DiaDexus grants SB a first right to negotiate with DiaDexus to
            obtain a non-exclusive or exclusive (as negotiated), world-wide
            license under DiaDexus IP generated during the Extended License
            Period to Make, Have Made, Use, and Sell rDx Service(s) in the field
            of Class I Dx Test(s).

            (b)   DiaDexus agrees to notify SB in writing of the commencement of
            such first right. SB and DiaDexus shall have a six (6) month period
            in which to negotiate and execute such license for such rDx Service,
            if the Parties mutually agree thereto. SB shall within thirty (30)
            days after receipt of such notice either accept in writing or
            decline such first right (no notice to DiaDexus within such thirty
            (30) day period shall constitute a waiver of such first right with
            respect to such rDx Service). If SB accepts such first right in
            writing, SB and DiaDexus agree to negotiate exclusively with each
            other in good faith effort to reach mutually acceptable agreement
            and to execute such agreement within such six (6) month period. In
            the event a license agreement is not entered into during such six
            (6) month period or a mutually agreed extension thereof, SB shall
            have no further right with respect to such rDx Service leaving
            DiaDexus free to pursue agreements with Third Parties or Incyte at
            its own discretion for such rDx Service.

5.3   DiaDexus Class II Dx Test(s) Grants: Subject to all the terms and
      conditions of this Agreement, DiaDexus hereby grants the following rights
      to SB and/or Incyte in the field of Class II Dx Test(s):

      5.3.1 cDx Homebrews

            (a)   DiaDexus grants SB a first right to negotiate with DiaDexus
            to obtain an exclusive license under DiaDexus IP generated during
            the

                                       26
<PAGE>   26
     Extended License Period, with the right to sublicense only to Incyte to
     Make, Have Made, Use and Sell cDx Homebrews in the field of Class II Dx
     Test(s) in the Homebrew Territory.

     (b)  DiaDexus agrees to notify SB in writing of the commencement of such
     first right. SB and DiaDexus shall have a six (6) month period in which to
     negotiate and execute such license for such cDx Homebrew if the Parties
     mutually agree thereto. SB shall within thirty (30) days after receipt of
     such notice either accept in writing or decline such first right (no
     notice to DiaDexus within such thirty (30) day period shall constitute a
     waiver of such first right with respect to such cDx Homebrew). If SB
     accepts such first right in writing, SB and DiaDexus agree to negotiate
     exclusively with each other in good faith effort to reach mutually
     acceptable agreement and to execute such agreement within such six (6)
     month period. In the event a license agreement is not entered into during
     such six (6) month period or a mutually agreed extension thereof, SB shall
     have no further right with respect to such cDx Homebrew.

     (c)  In the event SB declines such first right with respect to a cDx
     Homebrew, or fails to reach agreement with DiaDexus within the six (6)
     month period, DiaDexus grants Incyte the right to negotiate with DiaDexus
     to obtain an exclusive license under DiaDexus IP, with the right to
     sublicense only to SB, to Make, Have Made, Use, And Sell such cDx Homebrew
     in the field of Class II Dx Test(s) in the Homebrew Territory.

     (d)  DiaDexus agrees to notify Incyte in writing of the commencement of
     such right promptly after the earlier of when SB declines such first right
     or the expiration of the six (6) month period in which no agreement was
     reached with SB. SB and DiaDexus shall have a six (6) month period in
     which to negotiate and execute such license for such cDx Homebrew if the
     Parties mutually agree thereto. Incyte shall within thirty (30) days after
     receipt of such notice either accept in writing or decline such right (no
     notice to DiaDexus within such thirty (30) day period shall constitute a
     waiver of such right with respect to such cDx Homebrew). If Incyte accepts
     such right in writing, Incyte and DiaDexus agree to negotiate exclusively
     with each other in good faith effort to reach mutually acceptable
     agreement and to execute such agreement within such six (6) month period.
     In the event a license agreement is not entered into during such six (6)
     month period or a mutually agreed extension thereof, Incyte relinquishes
     any such right with respect to such cDx Homebrew and DiaDexus is free to
     enter into a license with respect to such cDx Homebrew with Third Parties.

5.3.2     rDx Service(s)

                                       27

<PAGE>   27
          (a)  DiaDexus grants SB and Incyte a first right to negotiate with
          DiaDexus to obtain a co-exclusive, world-wide license under DiaDexus
          IP generated during the Extended License Period, with the right to
          sublicense, to Make, Have Made, Use, and Sell rDx Service(s) in the
          field of Class II Dx Test(s).

          (b)  DiaDexus agrees to notify SB and Incyte in writing of the
          commencement of such first right. Each of SB and Incyte shall have a
          six (6) month period in which to negotiate with DiaDexus and execute a
          license for such rDx Service if such Parties mutually agree thereto.
          SB and Incyte shall each within thirty (30) days after receipt of such
          notice either accept in writing or decline such first right (no notice
          to DiaDexus within such thirty (30) day period shall constitute a
          waiver of such first right with respect to such rDx Service with
          respect to such Party). If SB and/or Incyte accept such first right in
          writing, SB and DiaDexus and/or Incyte and DiaDexus, each agree to
          negotiate exclusively with each other in good faith effort to reach
          mutually acceptable agreement and to execute such agreement within
          such six (6) month period. In the event a license agreement is not
          entered into during such six (6) month period or mutually agreed
          extension(s) thereof, SB or Incyte, as the case may be, shall have no
          further right with respect to such rDx Service.

5.4. DiaDexus Class III Dx Test(s) Grants: Subject to all the terms and
     conditions of this Agreement, DiaDexus hereby grants the following rights
     to SB and/or Incyte in the field of Class III Dx Test(s):

     5.4.1     cDx Homebrew(s)

          (a)  DiaDexus grants SB a first right to negotiate with DiaDexus to
          obtain an exclusive, world-wide license under DiaDexus IP, generated
          during the Extended License Period, with the right to sublicense only
          to Incyte, to Make, Have Made, Use, and Sell cDx Homebrew in the field
          of Class III Dx Test(s) in the Homebrew Territory.

          (b)  DiaDexus agrees to notify SB in writing of the commencement of
          such first right. SB and DiaDexus shall have a six (6) month period in
          which to negotiate and execute such license for such cDx Homebrew if
          the Parties mutually agree thereto. SB shall within thirty (30) days
          after receipt of such notice either accept in writing or decline such
          first right (no notice to DiaDexus within such thirty (30) day period
          shall constitute a waiver of such first right with respect to such cDx
          Homebrew). If SB accepts such first right in writing, SB and DiaDexus
          agree to negotiate exclusively with each

                                       28

<PAGE>   28

     other in good faith effort to reach mutually acceptable agreement and to
     execute such agreement within such six (6) month period. In the event a
     license agreement is not entered into during such six (6) month period or
     a mutually agreed extension thereof, SB shall have no further right with
     respect to such cDx Homebrew.

     (c)  In the event SB declines such first right with respect to a cDx
     Homebrew or fails to reach agreement with DiaDexus within a six (6) month
     period, DiaDexus grants Incyte the right to an exclusive license under
     DiaDexus IP, with the right to sublicense only to SB, to Make, Have Made,
     Use, and Sell Clinical Dx Homebrew(s) in the field of Class III Dx Test(s)
     in the Homebrew Territory.

     (d)  DiaDexus agrees to notify Incyte in writing of the commencement of
     such right promptly after the earlier of when SB declines such right or
     the expiration of the six (6) month period in which no agreement was
     reached with SB. Incyte and DiaDexus shall have a six (6) month period in
     which to negotiate and execute such license for such cDx Homebrew if the
     Parties mutually agree thereto. Incyte shall within thirty (30) days after
     receipt of such notice either accept in writing or decline such right (no
     notice to DiaDexus within such thirty (30) day period shall constitute a
     waiver of such right with respect to such cDx Homebrew). If Incyte accepts
     such right in writing, Incyte and DiaDexus agree to negotiate exclusively
     with each other in good faith effort to execute such agreement within such
     six (6) month period. In the event a license agreement is not entered into
     during such six (6) month period or a mutually agreed extension thereof,
     Incyte shall have no further right with respect to such cDx Homebrew and
     DiaDexus is free to enter into a license with respect to such cDx Homebrew
     with Third Parties.

5.4.2     rDx Service(s)

     (a)  DiaDexus grants Incyte a first right to negotiate with DiaDexus for
     an exclusive license under DiaDexus IP generated during the Extended
     License Period, with the right to sublicense, to Make, Have Made, Use, and
     Sell rDx Service(s) in the field of Class III Dx Test(s).

     (b)  DiaDexus agrees to notify Incyte in writing of the commencement of
     such first right. Incyte and DiaDexus shall have a six (6) month period in
     which to negotiate and execute such license for such rDx Service if the
     Parties mutually agree thereto. Incyte shall within thirty (30) days after
     receipt of such notice either accept in writing or decline such first
     right (no notice to DiaDexus within such thirty (30) day period shall
     constitute a waiver of such first right with respect to such rDx Service).
     If Incyte accepts

                                       29
<PAGE>   29
       such first right in writing, Incyte and DiaDexus agree to negotiate
       exclusively with each other in good faith effort to reach mutually
       acceptable agreement and to execute such agreement within such six (6)
       month period, provided such agreement contains a provision that such rDx
       Service shall be made available to SB on commercial terms. In the event a
       license agreement is not entered into during such six (6) month period or
       a mutually agreed extension thereof, Incyte shall have no further right
       with respect to such rDx Service as the case may be.

       (c) In the event Incyte declines such first right with respect to a rDx
       Service as the case may be, or fails to reach agreement with DiaDexus
       within a six (6) month period, DiaDexus grants SB and Incyte the
       co-exclusive right to a license(s) under such DiaDexus IP, with the right
       to sublicense, to Make, Have Made, Use, and Sell such rDx Service as the
       case may be in the field of Class III Dx Test(s).

       (d) DiaDexus agrees to notify SB in writing of the commencement of such
       right promptly after the earlier of when Incyte declines such right or
       the expiration of the six (6) month period in which no agreement was
       reached with Incyte. SB and Incyte and DiaDexus shall have a six (6)
       month period in which to negotiate and execute such license(s) for such
       rDx Service as the case may be. Incyte and/or SB shall within (30) days
       after receipt of such notice either accept in writing or decline such
       right (no notice to DiaDexus within such thirty (30) day period shall
       constitute a waiver of such right with respect to such rDx Service as the
       case may be). If Incyte and/or SB accept such right in writing, Incyte
       and/or SB, as the case may be, and DiaDexus agree to negotiate
       exclusively with each other in good faith effort to reach mutually
       acceptable agreement and to execute such agreement within such six (6)
       month period. In the event a license agreement is not entered into during
       such six (6) month period or a mutually agreed extension thereof, Incyte
       and SB shall have no further right with respect to such rDx Service as
       the case may be and DiaDexus is free to enter into a license with respect
       to such rDx Service with Third Parties.

5.5 DiaDexus Ix Product Grants: Subject to all the terms and conditions of this
    Agreement, DiaDexus hereby grants the following rights to Ix Products:

    5.5.1    Healthcare-Ix Products

       (a)   Subject to subparagraphs (b) and (c), DiaDexus grants SB and
       Incyte a world-wide, co-exclusive license, with the right to sublicense,
       under DiaDexus IP generated during the Extended License Period to Make,
       Have Made, Use, and Sell Healthcare-Ix Products, provided that such
       license is

                                       30
<PAGE>   30
        only sublicenseable by SB and Incyte if SB and Incyte mutually agree in
        writing to such sublicense.

        (b)  Unless DiaDexus otherwise elects at its discretion to accelerate
        the effective date of any license grant under Section 5.5.1(a) and
        subject to subparagraph (c) below, with respect to DiaDexus IP which is
        potentially useful as a Healthcare-Ix Product or portion thereof,
        DiaDexus's grant of rights to SB and Incyte under Paragraph 5.5.1(a)
        shall be effective upon the expiration of the two (2) year period
        following such calendar quarter during which such DiaDexus IP was
        generated (the "Proprietary Period").

        (c)  In the event DiaDexus elects, at its discretion, to grant rights to
        SB and Incyte under Paragraph 5.5.1(a) prior to expiration of the
        Proprietary Period, such license shall be subject to mutually agreed
        field of use restrictions in the field of Clinical Diagnostics.

    5.5.2    Research-Ix Products and Investigational-Ix Products

        (a)  Subject to subparagraphs (b) and (c), DiaDexus grants Incyte an
        exclusive, world-wide license, with the right to sublicense, under
        DiaDexus IP generated during the Extended License Period to Make, Have
        Made, Use, and Sell Research-Ix Products and Investigational-Ix
        Products.

        (b)  Unless at its discretion and subject to subparagraph (c) below,
        with respect to DiaDexus IP which is potentially useful as a Research-Ix
        Product or Investigational-Ix Product or portion(s) thereof, DiaDexus's
        grant of rights to Incyte under Paragraph 5.5.2(a) shall come into
        effect upon the expiration of the two (2) year period following such
        calendar quarter during which such DiaDexus IP was generated (the
        "Proprietary Period").

        (c)  In the event DiaDexus elects, at its discretion, to grant rights to
        Incyte under Paragraph 5.5.2(a) prior to expiration of the Proprietary
        Period, such license shall be subject to mutually agreed field of use
        restrictions in the field of Clinical Diagnostics.

5.6 Additional DiaDexus grants: Subject to all the terms and conditions of this
    Agreement, DiaDexus hereby grants the following additional rights to SB
    and/or Incyte:

    5.6.1    Improvements to SB Technology IP and Incyte Technology IP

        (a)  Notwithstanding anything else to the contrary, DiaDexus grants to
        Incyte a non-exclusive, paid-up, non-cancellable, royalty-free, license
        under

                                       31
<PAGE>   31
        DiaDexus IP which is an improvement to Incyte Technology IP generated by
        or on behalf of DiaDexus during the Extended License Period.

        (b)  Notwithstanding anything else to the contrary, DiaDexus grants to
        SB a non-exclusive, paid-up, non-cancellable, royalty-free, license
        under DiaDexus IP which is an improvement to SB Technology IP generated
        by or on behalf of DiaDexus during the Extended License Period.

5.6.2   Rx/Other

        (a)  Subject to subparagraphs (b), (c) and Paragraph 5.6.5(b), DiaDexus
        grants Incyte and SB world-wide license(s), with the right to
        sublicense, under DiaDexus IP generated during the Extended License
        Period to Make, Have Made, Use, and Sell any and all products and
        processes in the field of Rx/Other, as follows: such license(s) shall be
        co-exclusive to Incyte and SB except as to the license of an Invention
        as defined in Section 3.6.3 of the Incyte Collaborative LifeSeq(R)
        Database Agreement in the Pharmaceutical Field of Use in order to Make,
        Have Made, Use and Sell a Therapeutic Protein Product or Antisense
        Product, which such license(s) of DiaDexus IP shall be exclusive to
        Incyte.

        (b)  During the Extended License Period and with respect to all DiaDexus
        IP useful in the Rx/Other field, DiaDexus's disclosure of and grant of
        rights to SB and Incyte under Paragraph 5.6.2(a) shall only be disclosed
        and granted at the time such DiaDexus IP is the subject of a patent
        application filed by DiaDexus having a claim in the Rx/Other field and
        for which the relevant Gene Product(s) has been tested in diagnostic
        validation studies of at least twenty (20) patients.

        (c)  The parties agree that certain of SB's and Incyte's rights to
        DiaDexus IP in the field of Rx/Other are subject to existing obligations
        of SB and/or Incyte, as the case may be. For example,

                (i)  SB's co-exclusive rights in DiaDexus IP derived from Incyte
        Database Products are subject to applicable terms and conditions of the
        Incyte Database Agreements, including, in particular, the rights and
        obligations with respect to disclosure and sublicense of Incyte IP; and

                (ii) The obligations of SB to HGS pursuant to Paragraph
        5.6.5(b).

5.6.3   Bioinformatics

                                       32

<PAGE>   32

          DiaDexus hereby grants Incyte and SB a non-exclusive, sublicenseable
          license under DiaDexus IP generated during the Initial License Period
          in the field of Bioinformatics (which are not improvements to Incyte
          Technology IP or SB Technology IP) under reasonable commercial terms
          to be negotiated.

     5.6.4 Research

          DiaDexus hereby grants to SB a non-exclusive license under DiaDexus
          IP which is Clinical Non-genomic DiaDexus Data generated by or on
          behalf of DiaDexus during the Extended License Period, to use for its
          own internal research purposes.

     5.6.5 Other

          (a) For all Tests to which DiaDexus has lost its licenses to SB
          Diagnostic IP or Incyte Diagnostic IP, as the case may be pursuant to
          Paragraph 13.5, DiaDexus grants an exclusive, royalty-free,
          non-cancellable, world-wide license under DiaDexus IP, with the right
          to sublicense, to the extent necessary to Make, Have Made, Use, and
          Sell such Tests. Such license shall be granted back to the Party or
          Parties who made the original grant of SB Diagnostic IP or Incyte
          Diagnostic IP, as the case may be, upon which such Test was based.

          (b) Consistent with Paragraph 5.1.2, DiaDexus grants SB an exclusive,
          world-wide license, with the right to sublicense, under DiaDexus IP
          provided such DiaDexus IP was based on the use of or derived by SB
          Diagnostic IP identified by SB pursuant to Paragraphs 4.1.1 and
          9.1.5 as HGS Derived to Make, Have Made, Use, and Sell any and all
          products and processes other than Tests.

          (c) During the Extended License Period and for each cDx Kit
          manufactured by DiaDexus, DiaDexus grants SB most favored nation
          pricing with respect to the price of such cDx Kit sold to Third
          Parties.

          (d) During the Extended License Period and for each rDx Kit
          manufactured by DiaDexus, DiaDexus grants Incyte most favored nation
          pricing with respect to the price of such rDc Kit sold to Third
          Parties.

                      6.0 SCHEDULE OF PAYMENTS; ROYALTIES

6.1  Rx/Other Field of Use; Milestone Payments and Royalties to DiaDexus by SB
     and Incyte: Contingent on the following events, and subject to

                                       33
<PAGE>   33

          Paragraphs 6.5 and 6.6, the following payments and royalties shall be
          paid by SB or Incyte or their sublicensees, as the case may be, to
          DiaDexus for SB Rx Products and Incyte Rx Products, as the case may
          be, to DiaDexus for SB Rx Products and Incyte Rx Products, as the
          case may be, under the licenses granted under Paragraph 5.6.2(a) as
          applicable:

               (a) IND: A payment equal to (1) ******

               (b) Phase III Initiation: A payment equal to (1) ******

               (c) Regulatory Approval: A payment equal to (1) ******

               (d) Single Payment Obligation/Major Market: It is understood
               between the Parties that the payments above in subparagraphs
               (a)-(c) will not be made more than once with respect to each Rx
               Product and shall only be made when such obligation first occurs
               in a country of a Major Market.

               (e) Royalties on Net Sales: A royalty will be paid on Net Sales
               by SB or Incyte or their sublicensees, as the case may be, of
               any such Rx Product under the following schedule:

                    (i)  Rx Product subject to Paragraph: 6.5(a) 6.5(b) Rx
                    Product ********* ********

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

                                       34
<PAGE>   34

               (ii) In the event an Rx Product is sold in the form of a
               combination product containing at least one Rx Product and one
               or more other ingredients which are Therapeutically Active
               Ingredient(s), Net Sales of such combination product will be
               adjusted by multiplying actual Net Sales of such combination
               product by the fraction A/(A+B) where A is the average invoice
               price of the Rx Product, if sold separately, and B is the
               average invoice price of the Therapeutically Active
               Ingredient(s), if sold separately. If the Therapeutically Active
               Ingredient(s) are not sold separately, Net Sales shall be
               calculated by multiplying actual Net Sales of such combination
               product by the fraction A/C where A is the average invoice price
               of the Rx Product if sold separately, and C is the average
               invoice price of the combination product, provide A/C does not
               exceed one (1). If, neither the Rx Product nor the
               Therapeutically Active Ingredient(s) are sold separately, Net
               Sales shall be determined by the Parties in good faith. For the
               purposes of this Paragraph, Therapeutically Active Ingredient(s)
               shall mean an ingredient which is biologically active in
               achieving a clinical therapeutic effect but shall not include
               diluents, vehicles, drug delivery systems or specific adjuvants
               or any ingredient which does not have any, or only incidental,
               therapeutic properties when present alone, but does not include
               Rx Product.

          (f)  Licensing Revenue: SB or Incyte, as the case may be, shall pay
          DiaDexus ****** percent of Licensing Revenue for DiaDexus Patents
          licensed to Third Parties in the field of Rx/Other, only where such
          license is in the absence of the grant of rights to an Rx Product and
          payment of royalties and other payments to DiaDexus pursuant to
          subparagraphs (a)-(e).

6.2  RX/Other Field of Use; Milestone Payments and Royalties to Incyte by SB:
     Contingent on the following events, and subject to Paragraph 6.6, the
     following payments and royalties shall be paid for Rx Products under the
     licenses granted by DiaDexus to SB under Paragraphs 5.6.2(a) as applicable:

          (a) IND: a payment equal to ******

          (b) Phase III Initiation: A payment equal to ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

                                       15

<PAGE>   35

(c)     Regulatory Approval: A payment equal to ******

(d)     Single Payment Obligation/Major Market: It is understood between the
Parties that the payments above in subparagraphs (a)-(c) will not be made more
than once with respect to each Rx Product and shall only be made when such
obligation first occurs in a country of a Major Market.

(e)     Royalties on Net Sales: A ****** percent royalty will be paid by SB to
Incyte on Net Sales of any such SB Rx Product, provided:

(i)     The foregoing payments under subparagraphs (a)-(e) will accrue or
        become due or payable only with respect to Rx Products which are
        materially based on or use materially or are derived by material use of
        that which would constitute Incyte Database Know-How at the time of Use
        by DiaDexus (as defined in the Incyte Database Agreement(s)), which
        such Incyte Database Know-How was sublicensed by DiaDexus to SB as
        permitted by Paragraph 3.6.3 of the Incyte Database Agreement(s);

(ii)    In the event an Rx Product is sold in the form of a combination product
        containing at least one Rx Product and one or more other ingredients
        which are Therapeutically Active Ingredient(s), Net Sales of such
        combination product will be adjusted by multiplying actual Net Sales of
        such combination product by the fraction A/(A+B) where A is the average
        invoice price of the Rx Product, if sold separately, and B is the
        average invoice price of the Therapeutically Active Ingredient(s), if
        sold separately. If the Therapeutically Active Ingredient(s) are not
        sold separately, Net Sales shall be calculated by multiplying actual
        Net Sales of such combination product by the fraction A/C where A is
        the average invoice price of the Rx Product if sold separately, and C
        is the average invoice price of the combination product, provide A/C
        does not exceed one (1). If, neither the Rx Product nor the
        Therapeutically Active Ingredient(s) are sold separately, Net Sales
        shall be determined by the Parties in good faith. For the purposes of
        this Paragraph, Therapeutically Active Ingredient(s) shall mean an
        ingredient which is biologically active in achieving a clinical
        therapeutical effect but shall not include

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

                                       36
<PAGE>   36
            diluents, vehicles, drug delivery systems or specific adjuvants or
            any ingredient which does not have any, or only incidental,
            therapeutic properties when present alone, but does not include Rx
            Product.

6.3   Tests Field of Use; Payments and Royalties to DiaDexus by SB. Contingent
      on the following events, and subject to Paragraph 6.5 and 6.6, the
      following payments and royalties shall be paid by SB to DiaDexus for Tests
      under the licenses granted under Paragraph 5.2.1 as applicable:

            (a)   Royalties on Net Sales: A royalty will be paid on Net Sales by
            SB of any Test under the following schedule:

                  Test subject to Paragraph           6.5(a)            6.5(b)

            cDx Homebrew (Class I)                    ******            ******

            (b)   License Fee: Promptly upon the execution of each license
            agreement between SB and DiaDexus for each cDx Homebrew entered into
            pursuant to Paragraph 5.2.1, SB shall pay to DiaDexus a license fee
            of between ****** Such license fee is fully creditable against
            future royalties for such cDx Homebrew.

            (c)   Applicable Royalty Rate/License Fee: The applicable royalty
            rate for each such cDx Homebrew within such range specified in
            Paragraphs (a) shall be calculated as follows:

                  (i)   If the SB profit margin is ******

                  (ii)  If the SB profit margin is ******

                  (iii) For profit margins between ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

                                       37

<PAGE>   37
            (d) Other terms: All other terms of such license agreement entered
            into pursuant to Paragraph 5.2.1 for such cDx Homebrew to be
            negotiated pursuant to the relevant agreement between SB and
            DiaDexus with respect to such cDx Homebrew.

            (e) Other Tests
            SB and/or Incyte shall pay royalties to DiaDexus on Net Sales of
            Tests to which SB and/or Incyte has obtained rights from DiaDexus
            pursuant to this Agreement. Such royalty and other terms shall be
            negotiated pursuant to the relevant agreement negotiated between SB
            and/or Incyte and DiaDexus with respect to such Test.

6.4   Ix Product: Net Ix Revenue to DiaDexus by SB and Incyte. Contingent
      on the following events, and subject to Paragraph 6.6, the following
      payments shall be paid by SB and Incyte to DiaDexus for Ix Products, as
      the case may be, under the licenses granted under Paragraph 5.5 as
      applicable:

            Ix Revenue: SB or Incyte, as the case may be, shall pay DiaDexus
            ****** percent of Net Ix Revenue for such Ix Product; provided such
            Ix Product significantly incorporates DiaDexus data when sold.

6.5   Payment Obligation. The foregoing payment obligations of SB and Incyte to
      DiaDexus under Sections 6.1 and 6.3 will accrue or become due or payable
      only with respect to Rx Products and Tests:

            (a)   which but for the patent licenses granted herein would
            otherwise infringe a Valid Claim(s) of a DiaDexus Patent(s); or

            (b)   are covered by a pending claim of a DiaDexus Patent(s) but not
            a Valid Claim(s) of a DiaDexus Patent(s).

6.6   Duration of Royalty Payment Obligation.

      6.6.1    All Royalty obligations with respect to each Product under any
      portion of this Section 6.0 shall terminate on a country-by-country and
      product-by-product basis on the later of (i) ten (10) years after the
      first country-wide launch of each product in each country or (ii)
      expiration of the last-to expire Valid Claim which covers such product in
      each country.

      6.6.2    Upon termination of the royalty payment obligation, DiaDexus, SB,
      and Incyte, as the case may be, shall thereafter have in perpetuity a
      royalty-free license to make, use and sell such Product in the specified
      field(s) of use.

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

                                       38

<PAGE>   38
6.7       Royalties and Other Commitments to Third Parties

     6.7.1     DiaDexus acknowledges that SB has certain royalty and other
     commitments to Third Parties on certain of the SB Technology IP and/or SB
     Diagnostic IP. Where DiaDexus has commercialized or licenses a Test based
     on or derived by such SB Technology IP and/or SB Diagnostic IP, DiaDexus
     agrees to pay such royalties, either directly to such Third Party or via
     pass through payments to SB and to meet all of the other terms and
     conditions which such Third Party agreement may impose.

     6.7.2     DiaDexus acknowledges that Incyte has certain royalty and other
     commitments to Third Parties on certain of the Incyte Technology IP and/or
     Incyte Diagnostic IP. Where DiaDexus has commercialized or licenses a Test
     based on or derived by such Incyte Technology IP and/or Incyte Diagnostic
     IP, DiaDexus agrees to pay such royalties, either directly to such Third
     Party or via pass through payments to Incyte and to meet all of the other
     terms and conditions which such Third Party agreement may impose.

                         7.0    THIRD PARTY AGREEMENTS

7.1       Subject to Paragraph 7.2 and during the Initial License Period,
     Incyte and SB (including their Fifty Percent Affiliates) agree not to
     create new corporate entities formed for the primary purpose of making,
     having made, or selling cDx Kit(s).

7.2       During the Initial License Period, any new technology platform which
     is reasonably determined to be useful for making cDx Kit(s) to which SB or
     Incyte alone have the right to grant, or cause directly or indirectly to be
     granted, non-exclusive licenses consistent with the terms and conditions of
     this Agreement, SB or Incyte, as the case may be, shall offer DiaDexus a
     six (6) month period in which to negotiate and execute a non-exclusive
     license for such technology, under commercially reasonable terms. DiaDexus
     shall within thirty (30) days of receipt of such notice either accept in
     writing or decline such right (no notice to the other Party within such
     thirty (30) day period shall constitute a waiver of such right with respect
     to such technology license). If DiaDexus accepts such right in writing, the
     Parties agree to negotiate exclusively with each other in good faith effort
     to execute such agreement within such six (6) month period. In the event a
     non-exclusive license agreement is not entered into within such six (6)
     month period, SB or Incyte, as the case may be, shall be free to license
     such technology, or create a new entity, including joint ventures, which
     may utilize such technology in any field of use including cDx Kit(s)
     without obligation to DiaDexus. For any other such new technology platform
     which SB or Incyte, as the case may be, acquires a partial or restricted
     ownership interest during the Initial License Period, and if the partners
     in such new technology platform determine at their sole discretion to
     license to Third Parties for the purpose of Making, Having Made, Using, or
     Selling cDx Kits, SB or Incyte, as the

                                       39
<PAGE>   39
     case may be, will use commercially reasonable efforts to provide DiaDexus
     the opportunity to license such new technology platform non-exclusively.

7.3    Consistent with its obligations described herein, the Parties acknowledge
     that Incyte may exchange database access or satellite database services for
     cash, technology or equity with Third Party entities including companies
     which are involved in business related directly or indirectly to Clinical
     Diagnostic(s) without obligation to DiaDexus herein above.

7.4    Notwithstanding the provisions of this Agreement, SB and Incyte retain
     the right to undertake research and development programs or establish
     collaborations with Third Parties in any research area, including, but not
     limited to satellite database services, including areas which are or become
     the subject of this Agreement, provided, however that SB and Incyte remain
     subject to its confidentiality and license obligations to DiaDexus as set
     forth herein.

                         8.0  BIOINFORMATICS COMMITTEE

     8.1  Responsibilities of the Bioinformatics Committee

     8.1.1  Promptly following the Effective Date during the Initial License
          Period, the parties will form a committee made up of bioinformaticians
          from each Party (Bx Committee). The Bx Committee shall have the
          following responsibilities:

          (a)  Arrange for the orderly transfer of Bioinformatics to DiaDexus
          from SB and Incyte and to SB and Incyte from DiaDexus in accordance
          with the Agreement;

          (b)  Meet at least quarterly by phone or in person;

          (c)  Discuss possible collaborative efforts; and

          (d)  Any other duties as the members may mutually agree upon provided
          such duties are consistent with the terms and conditions of this
          Agreement.

                                       40

<PAGE>   40
                            9.0 INFORMATION EXCHANGE

      9.1   SB

      9.1.1       During the Initial License Period, SB shall use reasonable
            and ongoing efforts to disclose and supply to DiaDexus with certain
            SB Technology Know-How which is reasonably available and
            transferable, and has practical application in DiaDexus's research,
            development and commercialization activities pursuant to this
            Agreement. SB shall specify any prior Third Party obligations with
            respect to such SB Technology Know-How.

      9.1.2       During the Initial License Period, and consistent with the
            scope of applicable licenses granted herein, whenever SB reasonably
            determines that a Gene Product or set of Gene Product(s) (which
            Gene Product(s) are subject to Third Party obligations) may have
            utility as a Test, SB shall offer to DiaDexus any data, substances,
            processes, materials, formulae, know-how and inventions which are
            reasonably known to it with respect to such Gene Product or set of
            Gene Product(s) on a potential Test-by-potential Test basis, to the
            extent such data, substances, processes, materials, formulae,
            know-how and inventions are owned by SB or for which SB has a right
            to grant a license (including intellectual property obtained from
            Third Parties) consistent with the terms and conditions of this
            Agreement. SB will also notify DiaDexus of any obligations it would
            be required to undertake under Paragraph 6.7.1 as a result of
            accepting such. If DiaDexus decides to accept any such data,
            substances, processes, materials, formulae, know-how and inventions,
            such shall become SB Diagnostic Know-How and be listed on Appendix G
            and any corresponding SB Diagnostic Patents shall be listed on
            Appendix H.

      9.1.3       During the Initial License Period and consistent with the
            scope of the applicable license grants herein, whenever SB
            reasonably determines that a Gene Product or set of Gene Product(s)
            (which Gene Product(s) are not subject to Third Party obligations)
            may have utility as a Test, such data, substances, processes,
            materials, formulae, know-how and inventions which are reasonably
            known to it with respect to such Gene Product or set of Gene
            Product(s) shall become SB Diagnostic Know-How and be listed on
            Appendix G and any corresponding SB Diagnostic Patents shall be
            listed on Appendix H.

      9.1.4       SB agrees to notify DiaDexus in writing which SB Technology
            IP is sublicenseable by DiaDexus under this Agreement, any other SB
            Technology IP is not sublicenseable by DiaDexus.

                                       41
<PAGE>   41
      9.1.5       Prior to transfer to DiaDexus, SB agrees to notify DiaDexus
            in writing which SB Diagnostic IP is based on the use of or derived
            by the use of information derived from the HGS Agreements or other
            Third Party agreements, and to identify the commitments DiaDexus
            would be obliged to undertake under 6.7.1.

9.2   Incyte

      9.2.1       During the Initial License Period, Incyte shall use
            reasonable and ongoing efforts to disclose and supply to DiaDexus
            with certain Incyte Technology Know-How which is reasonably
            available and transferable, and has practical application in
            DiaDexus's research, development and commercialization activities
            pursuant to this Agreement. Incyte shall specify any prior Third
            Party obligations with respect to such Incyte Technology Know-How.

      9.2.2       During the Initial License Period, and consistent with the
            scope of the applicable license grants herein, whenever Incyte
            reasonably determines that a Gene Product on set of Gene Product(s)
            derived from laboratory data resulting from a prospective study
            which has been identified by Incyte as having utility as a
            potential cDx Homebrew, cDx Kit, or Class I rDx Kit or Class I rDx
            Service using standard biology laboratory techniques above and
            beyond bioinformatics analysis of data, Incyte shall offer to
            DiaDexus any such data, substances, processes, materials,
            formulae, know-how and inventions which are reasonably known to it
            with respect to such Gene Product or set of Gene Product(s) on a
            potential Test-by-potential Test basis, to the extent such data,
            substances, processes, materials, formulae, know-how and inventions
            are owned by Incyte or for which Incyte has a right to grant a
            license (including such intellectual property obtained from Third
            Parties) consistent with the terms and conditions of this
            Agreement. Incyte will also notify DiaDexus of any obligations it
            would be required to undertake under Paragraph 6.7.2 as a result of
            accepting such. If DiaDexus decides to accept any such data,
            substances, processes, materials, formulae, know-how and
            inventions, such shall become Incyte Diagnostic Know-How and be
            listed on Appendix B and any corresponding Incyte Diagnostic
            Patents shall be listed on Appendix C. DiaDexus acknowledges that
            disclosure or transfer of any Database Information as defined in
            the Incyte Database Agreement(s) in conjunction with know-how
            describing such potential cDx Homebrew, cDx Kit, or Class I rDx Kit
            or rDx Service, shall remain Database Information and remains
            subject to the terms and conditions of the Incyte Database
            Agreement(s).

                                       42
<PAGE>   42
    9.2.3      Incyte agrees to notify DiaDexus in writing which Incyte
        Technology IP is sublicenseable by DiaDexus under this Agreement, any
        other Incyte Technology IP is not sublicenseable by DiaDexus.

    9.2.4      Incyte agrees to notify SB in writing promptly after Incyte, in
        its sole discretion, decides to seek a marketing partner pursuant to
        Paragraph 3.5.

9.3     DiaDexus

    9.3.1      During the Extended License Period, DiaDexus shall use
        reasonable and ongoing efforts to disclose and supply to Incyte,
        DiaDexus IP which are improvements to Incyte Technology IP which are
        reasonably available and transferable.

    9.3.2      During the Extended License Period, DiaDexus shall use reasonable
        and ongoing efforts to disclose and supply to SB, DiaDexus IP which are
        improvements to SB Technology IP which are reasonably available and
        transferable.

    9.3.3      cDx Homebrew(s)

        During the Extended License Term and to the extent SB and/or Incyte have
        a right to a license, DiaDexus shall promptly notify SB (or Incyte as
        the case may be) in writing of any DiaDexus IP which is potentially
        useful as a specific cDx Homebrew and shall specify any prior Third
        Party obligations with respect to such DiaDexus IP.

    9.3.4      rDx Service(s)

        (a)    During the Extended License Term and to the extent SB has a right
        to a license, DiaDexus shall promptly notify SB in writing of any
        DiaDexus IP which is potentially useful as a rDx Service in the field of
        Class I or Class II Dx Test(s) and shall specify any prior Third Party
        obligations with respect to such DiaDexus IP.

        (b)    During the Extended License Term and to the extent Incyte has a
        right to a license, DiaDexus shall promptly notify Incyte in writing of
        any DiaDexus IP which is potentially useful as a rDx Service in the
        field of Class II or Class III Dx Test(s) and shall specify any prior
        Third Party obligations with respect to such DiaDexus IP.

    9.3.5      Healthcare-Ix Products

                                       43

<PAGE>   43
       (a) During the Extended License Term, and subject to the provisions of
       5.5.1, DiaDexus shall use reasonable and ongoing efforts to promptly and
       fully disclose to SB and Incyte all DiaDexus IP which is potentially
       useful as a Healthcare Ix Product which is reasonably available and
       transferable, and shall specify any prior Third Party obligations with
       respect to DiaDexus IP.

       (b) During the Extended License Term, whenever SB or Incyte identify a
       potential Healthcare-Ix Product opportunity received pursuant to
       Paragraph 9.3.5(a), SB or Incyte, as the case may be, shall disclose it
       to the others attention. Promptly after such disclosure, the Parties
       shall meet and shall mutually agree on the design and content of such
       Healthcare Ix Product.

  9.3.6    Research-Ix and Investigational-Ix Products

       (a) During the Extended License Term, and subject to the provisions of
       5.5.2, DiaDexus shall use reasonable and ongoing efforts to promptly and
       fully disclose to Incyte and DiaDexus IP which is potentially useful as
       a Research-Ix and Investigational-Ix Product which is reasonably
       available and transferable, and shall specify any prior Third Party
       obligations with respect to DiaDexus IP.

  9.3.7    DiaDexus IP which is Rx/Other

       (a) During the Extended License Period and subject to Paragraph 5.6.2,
       DiaDexus shall use reasonable and ongoing efforts to promptly and fully
       disclose to SB and Incyte all DiaDexus IP which is potentially useful in
       the Rx/Other field which is reasonably available and transferable, and
       shall specify any prior Third Party obligations with respect to DiaDexus
       IP.

  9.3.8    Bioinformatics

       (a) During the Extended License Term, DiaDexus shall promptly and fully
       disclose to Incyte and SB any DiaDexus IP which is Bioinformatics and
       subject to the provisions of Paragraph 5.6.3 which is reasonably
       available and transferable, and shall specify any prior Third Party
       obligations with respect to DiaDexus IP.

  9.3.9    Other

       (a) During the Extended License Period, and with respect to DiaDexus IP
       which is subject of any license granted to SB or Incyte under Section 5,
       DiaDexus shall use reasonable and ongoing efforts to disclose and supply

                                       44

<PAGE>   44
       to SB or Incyte, as the case may be, with that certain DiaDexus IP which
       is reasonably available and transferable and the subject of such license.

       (b) Notwithstanding anything else to the contrary, DiaDexus IP which is
       based on the use of or derived by the use of HGS derived SB Diagnostic IP
       as provided to DiaDexus pursuant to Paragraph 9.1.2 shall only be
       disclosed to SB.

       (c) Incyte Database Technology shall only be disclosed to SB by DiaDexus
       in accordance with the Incyte Database Agreement(s).

                            10.0  RESEARCH COMMITTEE

10.1   Research Committee(RC): Promptly after the Effective Date the Parties
       shall form an RC and each designate their membership on such committee.
       The RC shall meet at least quarterly during the Initial License Period.

10.2   Responsibilities of the RC:

       (i) The orderly transfer of DiaDexus IP, SB Diagnostic IP, SB Technology
       IP, Incyte Diagnostic IP, and Incyte Technology IP pursuant to the terms
       and conditions of this Agreement;

       (ii) Receiving Research Plans; and

       (iii) Any other responsibilities consistent with the terms and conditions
       of this Agreement and which the Parties mutually agree on.

                               11.0 RESEARCH PLAN

11.1   Filing of Research Plans

       (a) A Research Plan may only be submitted to the RC by DiaDexus and only
       during the Initial License Period.

       (b) Incyte and/or SB may request DiaDexus to submit a Research Plan with
       respect to Incyte Diagnostic IP and/or SB Diagnostic IP for which a
       Research Plan has not been filed with eighteen (18) months after transfer
       to DiaDexus. If six (6) months after such request, DiaDexus has not filed
       such Research Plan, such Incyte Diagnostic IP and/or SB Diagnostic IP
       shall revert to SB and/or Incyte as the case may be pursuant to Section
       13.

11.2   Updating Research Plans

                                       45
<PAGE>   45

          Within thirty (30) days after the end of June 30 and December 31
          respectively, DiaDexus shall provide to the RC in writing
          semi-annual reports with respect to work performed by or for it under
          each Research Plan which shall consist of updates substantially in
          the form of Appendix F.

                                       46
<PAGE>   46

                     12.0  CONFIDENTIALITY AND PUBLICATION

    12.1  Confidentiality obligations. Each Party acknowledges that during the
          course of this Agreement and pursuant to this Agreement it will
          receive information (the "Receiving Party") from another Party or
          Parties which is proprietary, confidential and of commercial value to
          such Party, the "Disclosing Party". For purposes of this Agreement,
          "Confidential Information" shall mean technical and business
          information belonging to the Disclosing Party which is disclosed
          pursuant to this Agreement, including, where appropriate and without
          limitation, any information, business, financial and scientific data,
          Gene Product(s), patent disclosures, patent applications, structures,
          models, techniques, processes and, compositions, compounds, biological
          samples, apparatus, and the like, and bioinformatics methods, hardware
          configurations and software in various stages of development or any
          software product (source code, object code or otherwise, including
          its audiovisual components (menus, screens, structure and
          organization) and any human or machine readable form of the program,
          and any writing or medium in which the program or information therein
          is stored, written or described, including, without limitation,
          diagrams, flow charts, designs, drawings, specifications, models,
          data, bug reports, and the like. Except to the extent expressly
          authorized by this Agreement, the Receiving Party agrees that, for
          the Initial License Period and for ten (10) years thereafter, it
          shall keep confidential and shall not publish or otherwise disclose
          and shall not use for any purpose (except those expressly permitted
          under this Agreement) any Confidential Information furnished to it by
          a Disclosing Party pursuant to this Agreement, and regardless of the
          medium on which it is provided, including know-how, except to the
          extent that it can be established by the Receiving Party by competent
          proof that such information:

               (a)  was already known to it, other than under an obligation of
               confidentiality, at the time of disclosure by the Disclosing
               Party;

               (b) was generally known to the public or otherwise part of the
               public domain at the time of its disclosure to it;

               (c) became generally available to the public or otherwise part
               of the public domain after its disclosure other than through any
               act or omission of it in breach of this Agreement;

               (d) was subsequently lawfully disclosed to it by a Third Party;

                                       47
<PAGE>   47
          (e)  was independently discovered or developed by it without the use
          of the Disclosing Party's Confidential Information, as can be
          documented by written records created at the time of such independent
          discovery or development.

12.2 Disclosure. The Receiving Party may disclose the other's Confidential
     Information to the extent such disclosure is reasonably necessary in (i)
     filing, prosecuting patent applications and maintaining patents (consistent
     with Section 14); (ii) prosecuting or defending litigation; and (iii)
     complying with applicable governmental regulations provided, however, that
     if it is required to make any disclosure of the Disclosing Party's secret
     or Confidential Information it will give reasonable advance notice to the
     Disclosing Party of such disclosure requirement and will use its reasonable
     efforts to secure confidential treatment of such information required to be
     disclosed. The Parties shall cooperate in any patent filing under
     subparagraph (i) of this Paragraph.

12.3 Publication; Third Party Access. Except as provided for in Paragraph 12.2,
     Confidential Information of a Disclosing Party will not be published by
     DiaDexus or disclosed in any form by DiaDexus, except as follows:

          (a)  DiaDexus and its sublicensees may publish scientific results of
          their work within the scope of the licenses granted under this
          Agreement, provided, however, that:

               (i) any such publication by DiaDexus or its sublicensees that
               would disclose Confidential Information of a Disclosing Party
               shall require the prior consent of such Party, which consent will
               not be unreasonably withheld or delayed, provided that such
               disclosure is on a Test-by-Test basis and DiaDexus has taken
               necessary steps to provide for diligent review by the Disclosing
               Party for removal of, or approval to disclose, Disclosing Party's
               Confidential Information; and

               (ii) a Research Plan has been filed pursuant to Section 11 with
               respect to the Gene Product(s) which are the subject of such
               Confidential Information; and

               (iii) any such publications will include recognition of the
               contributions of the Disclosing Party according to standard
               practice for assigning scientific credit, either through
               authorship or acknowledgment as may be appropriate.

                                       48

<PAGE>   48
        (b)  Any scientific publications of a Party that would disclose
        Confidential Information of another Party on other than an individual
        Gene Product basis shall be under reasonable terms and conditions
        mutually agreed between the Parties, including the provisions of
        subparagraphs (i) to (iii) above.

        (c)  SB and Incyte recognize that DiaDexus, in the normal course of
        business, utilizes consultants and academic collaborators who are bound
        by a contractual obligation to DiaDexus, including an obligation of
        confidentiality to DiaDexus. DiaDexus may disclose Confidential
        Information of a Disclosing Party on a Test-by-Test basis to such
        consultants and academic and Third Party collaborators in the context of
        the disclosure of DiaDexus's own scientific results or the conduct of
        its work within the scope of the licenses granted herein, provided,
        however, that:

            (i)  DiaDexus has obtained a written obligation of confidentiality
            and appropriate use restrictions no less restrictive than those set
            forth herein and provided that such Third Party shall not further
            disclose Confidential Information; and

            (ii)  any such disclosure of Confidential Information which includes
            the transfer of DNA sequence information or biological materials
            shall be subject to a written materials transfer agreement which
            protects the intellectual property rights of SB, Incyte, and
            DiaDexus as set forth herein, such agreement to include customary
            provisions regarding scope of work, publication, protection or
            proprietary subject matter and ownership of inventions; and

            (iii)  a Research Plan has been filed pursuant to Section 11 with
            respect to the Gene Product(s) which are the subject of such
            Confidential Information; and

            (iv)  DiaDexus has obtained a written obligation from such Third
            Party regarding the Disclosing Party's right to review publications
            as under the provisions of Paragraph 12.2 herein.

        (d)  With respect to the transfer of Confidential Information of a Party
        on other than a Class I Test basis or an individual Gene Product basis,
        the Disclosing Party agrees to obtain the prior

                                       49
<PAGE>   49
          written consent of the Party who is the source of such Confidential
          Information with respect to such Third Party transfer, and the source
          Party retains the right to review and approve the relevant sections of
          the written materials transfer agreement between the disclosing Party
          and such Third Party, with such consent and approval not to be
          unreasonably withheld.

12.4 Except as expressly provided for herein, this Section 12 shall not be
     construed to allow DiaDexus, its sublicenses, collaborators or consultants
     to publish or disclose Incyte Diagnostic IP, Incyte Technology IP, SB
     Diagnostic IP, and SB Technology IP at any time without the express written
     consent of the Disclosing Party.

12.5 Nothing herein shall be construed as preventing SB or Incyte from
     disclosing any DiaDexus information to an Affiliate of a Party or to a
     sublicensee, distributor or joint venture or other associated company of
     either party for the purpose of developing or commercializing a Product
     consistent with the grants herein, provided such Affiliate, sublicensee,
     distributor or joint venture or other associated company has undertaken a
     similar obligation of confidentiality with respect to the confidential
     information.

12.6 All Confidential Information disclosed by one party to the other shall
     remain the intellectual property of the disclosing party. In the event that
     a court or other legal or administrative tribunal, directly or through an
     appointed master, trustee or receiver, assumes partial or complete control
     over the assets of a party to this Agreement based on the insolvency or
     bankruptcy of such party, the bankrupt or insolvent party shall promptly
     notify the court or other tribunal (i) that Confidential Information
     received from another Party under this remains the property of the other
     party and (ii) of the confidentiality obligations under this Agreement. In
     addition, the bankrupt or insolvent Party shall, to the extent permitted by
     law, take all steps necessary or desirable to maintain the confidentiality
     of the other party's Confidential Information and to insure that the court,
     other tribunal or appointee maintains such information in confidence in
     accordance with the terms of this Agreement.

                                 13.0 DILIGENCE

13.1 Development, registration, and commercialization: Each Party shall have
     full control and authority over development, registration and
     commercialization of Products it has rights to develop and commercialize
     pursuant to this Agreement.

                                       50
<PAGE>   50
13.2   Significant developments: The parties shall keep the other informed of
     significant developments in its (and its licensees where relevant)
     progress of its efforts to develop and commercialize royalty bearing
     Products or Products to which another Party may have rights to under this
     Agreement.

13.3   Diligent efforts: Each Party shall use its diligent efforts to develop,
     market, promote and sell any Product as to which such Party obtains rights
     to under this Agreement. Such diligent efforts shall be equivalent to those
     efforts it uses with respect to products of similar value and status.

13.4   cDx/rDx: To the extent permitted by law, in the event one Party is
     selling a Test as a cDx Kit or rDx Service and another Party is selling the
     same test in the same country or territory in the form of an rDx Kit or rDx
     Service, the parties agree to apply consistent and appropriate marketing
     and labeling efforts so that such rDx Kit or rDx Service is not used as a
     cDx Kit or Homebrew and vice versa.

13.5   Due Diligence/Reversion Exclusive License: Consistent with its
     obligations under Paragraph 13.3, in the event DiaDexus and/or its
     sublicensees are not selling a given cDx Kit and/or cDx Homebrew or are
     not actively researching or developing a given cDx Kit or cDx Homebrew
     (each for which DiaDexus has been granted an exclusive license hereunder)
     for a period in excess of six (6) months and for which DiaDexus has been
     granted a license to Incyte Diagnostic IP or SB Diagnostic IP as the case
     may be, such license to such cDx Kit or cDx Homebrew shall immediately
     terminate, provided DiaDexus has received written notice from Incyte or SB
     promptly after submission to the Research Committee of a Research Plan
     with respect to such cDx Kit or cDx Homebrew and further provided that
     DiaDexus has not demonstrated in writing within thirty (30) days of such
     notice to SB or Incyte, as the case may be, that DiaDexus or its licensees
     has been selling such cDx Kit or cDx Homebrew, as the case may be, or has
     been actively researching or developing, including reasonable efforts to
     sublicense as permitted under this Agreement, any such cDx Kit or cDx
     Homebrew, as the case may be.

13.6   DiaDexus Non-Exclusive Licenses

     13.6.1  Due Diligence. DiaDexus agrees to use due diligence to pursue the
     development, governmental approval and commercial exploitation of Tests
     for which DiaDexus has been granted a non-exclusive license to Incyte
     Diagnostic IP or SB Diagnostic IP, as the case may be. DiaDexus's
     obligation to use due diligence shall require a level of effort consistent
     with that applied by DiaDexus towards its other tests with similar
     commercial potential.

     13.6.2  Reversion. With respect to any Tests for which DiaDexus has been
     granted a non-exclusive license to Incyte Diagnostic IP or SB Diagnostic
     IP as the case may be, if

                                       51
<PAGE>   51
DiaDexus fails, abandons or suspends the development or commercialization of any
such Tests, including reasonable efforts to sublicense, then Incyte or SB, as
the case may be, shall have the right, in its sole discretion upon written
notice to DiaDexus, to terminate such license with respect to such Test.

                                       52
<PAGE>   52
            14.0 PATENT PROSECUTION AND PATENT LITIGATION

14.1 Ownership: Each Party shall have and retain sole and exclusive title to all
     inventions, discoveries and know-how (together with all intellectual
     property rights therein and thereto) which are made, conceived, reduced to
     practice or generated solely by its employees, agents, or other persons
     acting under its authority in the course of or as a result of this
     Agreement. A Party shall own an equal and undivided interest with another
     Party (or Parties as the case may be) in all inventions, discoveries and
     know-how (together with all intellectual property rights therein and
     thereto) made, conceived, reduced to practice or generated jointly by
     employees, agents, or other persons acting under the authority of another
     Party (or Parties) in the course of or as a result of this Agreement, and
     such Party shall have the right, subject to the provisions of this
     Agreement, to freely exploit, transfer, license or encumber its interest in
     such jointly owned intellectual property rights without the consent of, or
     payment or accounting to, the other Party(ies).

14.2 Disclosure by SB and Incyte: SB and Incyte shall only be required to
     disclose to DiaDexus the complete texts of all patent applications filed
     by it which relate to Tests for which DiaDexus has an exclusive license
     hereunder as well as all information received concerning the institution or
     possible institution of any interference, opposition, re-examination,
     reissue, revocation, nullification or any official proceeding involving a
     patent covering such Test ("Patents"), provided DiaDexus requests such
     information in writing from SB or Incyte, as the case may be. DiaDexus, at
     its expense, shall have the right to review all such pending applications
     and other proceedings and make recommendations to SB or Incyte, as the case
     may be, concerning them and their conduct. SB and Incyte agree to keep
     DiaDexus reasonably informed of the course of patent prosecution or other
     proceedings of such Patents including by providing DiaDexus with copies of
     substantive communications, search reports and Third Party observations
     submitted to or received from patent offices. DiaDexus shall provide such
     patent consultation at no cost. DiaDexus shall hold all information
     disclosed to it under this section as Confidential Information and subject
     to the provisions of Section 12.

14.3 Assumption of rights: For Patents for which DiaDexus has been granted an
     exclusive license and to the extent possible, DiaDexus shall have the right
     to assume responsibility for any Patent or any part of a Patent which SB or
     Incyte intends to abandon or otherwise cause or allow to be forfeited for
     the limited purpose of obtaining claims which cover Tests to which DiaDexus
     retains a license hereunder. SB and Incyte shall give DiaDexus reasonable
     written notice prior to abandonment or other forfeiture of any such Patent
     or any part of a Patent so as to permit DiaDexus to exercise its rights
     under this paragraph.

14.4 DiaDexus Patents: DiaDexus shall have the right within its sole discretion
     and at its expense to prepare, file, prosecute and maintain its patents
     ("DiaDexus Patents") for

                                       53
<PAGE>   53
      which neither SB nor Incyte are named as inventors. With respect to
      DiaDexus Patents as to which SB and/or Incyte retains a license hereunder,
      DiaDexus shall keep SB and/or Incyte, as the case may be, reasonably
      informed with respect to the filing and prosecution thereof. In the event
      that SB or Incyte desires that DiaDexus obtain and maintain patent
      protection in any country with respect to DiaDexus IP as to which SB
      and/or Incyte, as the case may be, retains a license hereunder, DiaDexus
      shall do so at the cost and expense of SB and/or Incyte, as the case may
      be.

14.5  Third Party Infringement: A Party will notify the other Parties if it
      becomes aware of the activities of any Third Party which are believed to
      infringe any of the patent rights licensed exclusively hereunder. DiaDexus
      and SB or Incyte as the case may be, as the party licensing the patent at
      issue to DiaDexus, including sublicensee(s) as appropriate, shall consult
      with each other as to a potential litigation strategy or strategies
      against an alleged infringer and may jointly use reasonable commercial
      efforts to terminate such alleged infringement without litigation.

      15.5.1      If such efforts of DiaDexus and the Party licensing such
            patent to DiaDexus are not successful in abating the alleged
            infringement:

            a)    within sixty (60) days of such determination, DiaDexus and
            licensor may elect to commence and prosecute a suit jointly, with
            litigation strategy and any settlement of such proceedings subject
            to the approval of the Party licensing such patent to DiaDexus;

            b)    DiaDexus, shall have the right to bring and maintain any
            appropriate suit or action involving such infringement, at its own
            expense provided the Party licensing such patent to DiaDexus has
            declined in writing to bring such suit or action;

      15.5.2      In the instance in which one Party institutes such
            infringement actions, the other Parties agree, to execute all papers
            and perform such other acts as may be reasonably required (including
            consent to be joined as nominal Party plaintiffs in such action),
            such to be at the request and expense of the Party bringing suit.
            The other Parties will be provided reasonable opportunities to
            advise or comment regarding litigation strategy and settlement of
            such proceedings, and may, at their option and expense, be
            represented by counsel of their choice. No Party may settle any
            action or otherwise consent to an adverse judgment in an action that
            diminishes the rights or interests of another Party without the
            prior written consent of such other Party.

      14.5.3      Any amount recovered in any action or suit, whether by
            judgment or settlement, shall first be applied to reimburse pro rata
            the costs of litigation to the Party or Parties which paid such
            costs. Any remaining amount shall be used to reimburse licensor(s)
            which have paid such costs for any royalties which have been

                                       54
<PAGE>   54
          reduced by virtue of this provision. Any remaining amount shall be
          divided in the same proportion as the Parties paid the associated
          attorney's fees and Third party litigation expenses.

     14.5.4    In the event of the institution of any suit by a Third Party
          against DiaDexus, or its sublicenses or distributors for patent
          infringement of rights licensed exclusively hereunder and involving
          the manufacture, use, sale, distribution or marketing of Test,
          DiaDexus shall promptly notify the Licensor in writing. DiaDexus
          shall have the right but not the obligation to defend such suit at
          its own expense. DiaDexus and Licensor shall assist one another and
          cooperate in any such litigation at the other's request without
          expense to the requesting Party.

14.6 Freedom From Suit

     14.6.1    With respect to composition of matter claims directed to Gene
          Products which are materially based on or are derived by material use
          of that which would constitute Incyte Diagnostic IP, which are owned
          or controlled by DiaDexus, (or DiaDexus Affiliate(s) or
          sublicensee(s) as the case may be), DiaDexus (or DiaDexus
          Affiliate(s) or sublicensee(s) as the case may be) agrees to sue or
          bring any action in any court or administrative agency or any other
          government authority alleging infringement of said claims as a result
          of activities or Incyte or Incyte Affiliates or sublicensee(s) with
          respect to rDx Service(s) or rDx Kit(s) or Ix Product(s) which would
          constitute an infringement of said patents, and further, DiaDexus (or
          DiaDexus Affiliate(s) or sublicensee(s) as the case may be) agrees to
          extend such freedom from suit or action to further sublicensee(s) of
          Incyte, Incyte Affiliates, or licensees with respect to such rDx
          Services or rDx Kits or Ix Product(s).

     14.6.2    With respect to composition of matter claims directed to Gene
          Products which are materially based on or are derived by material use
          of that which would constitute SB Diagnostic IP, which are owned or
          controlled by DiaDexus (or DiaDexus Affiliate(s) or sublicensee(s) as
          the case may be), DiaDexus (or DiaDexus Affiliate(s) or
          sublicensee(s) as the case may be) agrees not to sue or bring any
          action in any court or administrative agency or any other government
          authority alleging infringement of said claims as a result of
          activities of SB or SB Affiliates or sublicensee(s) with respect to
          rDx Service(s) or rDx Kit(s) or Ix Product(s) which would constitute
          an infringement of said patents, and further, DiaDexus (or DiaDexus
          Affiliate(s) or sublicensee(s) as the case may be) agrees to extend
          such freedom from suit or action to further sublicensee(s) of SB, SB
          Affiliates, or licensees with respect to such rDx Services or rDx
          Kits or Ix Product(s).

                                       55

<PAGE>   55

                        15.0  STATEMENTS AND REMITTANCES

15.1  Records: A Party, as the case may be, shall keep and require its licensees
      to keep complete and accurate records of all Net Sales, Net Ix Revenues,
      and Licensing Revenues subject to royalties and/or payments under the
      licenses granted herein. The Party owed such royalties and/or payments
      shall have the right, at its expense, through a certified public
      accountant or like person reasonably acceptable to the other Party, to
      examine such records during regular business hours during the life of this
      Agreement and for six (6) months after its termination; provided, however,
      that such examination shall not take place more often than once a year and
      provided further that such accountant shall report only as to the accuracy
      of the royalty statements and payments, including the magnitude and source
      of any discrepancy. No Party nor their licensees shall be required to
      maintain such records for more than two (2) years with respect to any
      given Net Sales, Net Ix Revenues or Licensing Revenues. If such
      examination reveals an underpayment of royalties or other payments by ten
      percent (10%) or more, the underpaying Party shall pay all costs of such
      examination. In the event such accountant concludes that additional
      royalties or payments were owed, the additional royalties shall be paid
      within thirty (30) days of the date the accounting Party delivers to
      underpaying Party such accountant's written report so concluding. If such
      examination reveals an underpayment of royalties or other payments by less
      than ten percent (10%), the auditing Party shall pay all costs of such
      examination.

15.2  Accounting: Within sixty (60) days after the close of each calendar
      quarter, each Party shall deliver to the Party owed a royalty and/or
      payment hereunder a true accounting of all Products and/or Ix Products
      sold or licensed by it and its licensees and distributors during such
      quarter for which royalties and/or payments are payable and shall at the
      same time pay all royalties due. Such accounting shall show sales on a
      country-by-country and product-by-product basis.

15.3  Currency: All royalties due under this Agreement shall be payable in U.S.
      dollars. If governmental regulations prevent remittances from a foreign
      country with respect to sales made in that country, the obligation to pay
      royalties on sales in that country shall be suspended until such
      remittances are possible.

15.4  Monetary conversion:

      15.4.1      Monetary conversions from the currency of a foreign country,
      in which a product is sold, into United States currency shall be made at
      the official exchange rate in force in that country for financial
      transactions on the last business day of the calendar quarter or half year
      for which the royalties are being paid. If there is no such official
      exchange rate, the conversation shall be made at the rate for such
      remittances on that date as certified by Citibank, N.A., New York, New
      York, U.S.A.

                                       56
<PAGE>   56
     15.4.2 Monetary conversions with respect to payments made by SB from the
     currency of a foreign country, in which a product is sold, into United
     States currency shall be calculated at the actual average rates of exchange
     for the year to date as used by SB in producing its quarterly and annual
     accounts, as confirmed by SB's auditors.

15.5 Mode of Payment: Ix Product. For purposes of determining when a license of
     a royalty-bearing Ix Product occurs, the license shall be deemed to occur
     on the date of the receipt of payments from the Third Party end user of the
     Ix Product.

15.6 Mode of Payment. For purposes of determining when a sale of a
     royalty-bearing Product occurs, the sale shall be deemed to occur on the
     date of the invoice to the purchaser of the Product.

                            16.0  TERM; TERMINATION

16.1 Term; Termination at Full Term. Unless earlier terminated as provided
     herein, this Agreement shall commence as of the Effective Date and shall
     remain in full force and effect until the termination of the last to expire
     payment obligations of any Party.

16.2 Breach.

     16.2.1 Failure by any Party to comply with any of the material obligations
     contained in this Agreement shall entitle the other Party(ies) to give to
     the Party in default notice specifying the nature of the default and
     requiring it to make good such default. If such default is not cured
     within ninety (90) days after the receipt of such notice, the notifying
     Party(ies) shall be entitled, without prejudice to any of its other rights
     conferred on it by this Agreement, in addition to any other remedies
     available to it by law or in equity, immediately to terminate this
     Agreement by giving written notice to the Party in default provided the
     other non-breaching Party agrees in writing to such termination. The right
     of a Party to terminate this Agreement, as hereinafter provided, shall not
     be affected in any way by its waiver or failure to take action with
     respect to any previous default.

     16.2.2  In the event a Party fails to make a payment to another with
     respect to a Product due under this Agreement when due, in addition to any
     other remedy which it may have, such Party may notify the non-paying Party
     in writing that all of such Party's rights with respect to such Product
     shall terminate as of thirty (30) days after such written notice and such
     Party's rights with respect thereto shall terminate unless such payment is
     made or such failure is cured, prior to the expiration of such thirty (30)
     day period.

16.3 Insolvency or Bankruptcy. To the extent permitted by applicable law, a
     Party (Termination Party) may, in addition to any other remedies available
     to it by law or in equity, terminate this Agreement, in whole or in part
     as the Terminating Party may

                                       57

<PAGE>   57
      determine, by written notice to the other Party in the event the other
      Party shall have become insolvent or bankrupt, or shall have made an
      assignment for the benefit of its creditors, or there shall have been
      appointed a trustee or receiver of the other Party or for all or a
      substantial part of its property, or any case or proceeding shall have
      been commenced or other action taken by or against a Party in bankruptcy
      or seeking reorganization, liquidation, dissolution, winding-up,
      arrangement, composition or readjustment of its debts or any other relief
      under any bankruptcy, insolvency, reorganization or other similar act or
      law of any jurisdiction now or hereafter in effect.

16.4  Accrued Surviving Obligations. Upon any termination, relinquishing or
      expiration of this Agreement, the following provisions will not terminate,
      but will continue in full force and effect:  Section 6, 12, 13, 14, 15,
      18, and 19 and any other terms and conditions of this Agreement clearly
      meant to survive termination.

16.5  DiaDexus Test Sublicensees: Upon termination of this Agreement pursuant to
      Paragraph 16.2 or Paragraph 16.3 thereof in the event of the bankruptcy or
      similar event listed in such Paragraph 16.3 and if a sublicensee of
      DiaDexus Test requests, then SB and/or Incyte, as the case may be, shall
      grant direct licenses to such sublicensees for such Tests provided that,
      (a) the scope of the direct licenses to the Third Party shall be no
      greater than the scope of the sublicense granted by DiaDexus for such
      Test; (b) SB and/or Incyte shall have no more obligations owing to the
      Third Party sublicensee under the direct licenses than their respective
      obligations under this Agreement, (c) the sublicensee is in compliance
      with all the terms and conditions of the sublicense, and (d) all
      consideration for the direct licenses which are not otherwise payable
      under the Incyte Database Agreements or subject to Third Party
      obligations, shall be retained equally by the non=terminated Parties
      granting such direct licenses.

            17.0  REPRESENTATIONS AND WARRANTIES; COVENANTS

17.1  Representations and Warranties.  Each Party represents and warrants to the
      other Parties that:

      (a)   it has the corporate power and authority and the legal right to
      enter into this Agreement and to perform its obligations hereunder.

      (b)   the execution and delivery of this Agreement and the performance of
      the transactions contemplated hereby have been duly authorized by all
      necessary corporate action of such Party;

      (c)   to such Party's knowledge, the execution and delivery of this
      Agreement and the performance by such Party of any of its obligations
      under this Agreement do not and will not (i) conflict with, or constitute
      a breach or violation of, any other contractual obligation to which it is
      a Party, any judgment of any court or governmental body

                                       58
<PAGE>   58
        applicable to such Party or its properties or, any statute, decree,
        order, rule or regulation of any court or governmental agency or body
        applicable to such Party or its properties, and (ii) with respect to the
        execution and delivery of this Agreement, require any consent or
        approval of any governmental authority or other person;

        (d)  there are no material adverse proceedings, claims or actions
        pending, or to the best of Incyte's knowledge, threatened, relating to
        the Incyte Technology IP and Incyte Diagnostic IP as of the Effective
        Date of this Agreement which would materially interfere with Incyte's
        performance of its obligations under this Agreement. Further, Incyte
        shall to the best of its knowledge without undertaking a special
        investigation, disclose to DiaDexus any material adverse proceedings,
        claims or action that arise, relating to such Incyte Technology IP and
        Incyte Diagnostic IP during the Initial License Period, which would
        materially interfere with Incyte's performance of its obligations under
        this Agreement.

        (e)  there are no material adverse proceedings, claims or actions
        pending, or to the best of SB's knowledge, threatened, relating to the
        SB Technology IP and SB Diagnostic IP as of the Effective Date of this
        Agreement which would materially interfere with SB's performance of its
        obligations under this Agreement. Further, SB shall to the best of its
        knowledge without undertaking a special investigation, disclose to
        DiaDexus any material adverse proceedings, claims or action that arise,
        relating to such SB Technology IP and SB Diagnostic IP during the
        Initial License Period, which would materially interfere with SB's
        performance of its obligations under this Agreement.

        (e) to the best of its knowledge without undertaking a special
        investigation, DiaDexus shall disclose to SB and Incyte any material
        adverse proceedings, claims or action that arise, relating to DiaDexus
        IP during the Extended License Period, which would materially interfere
        with its performance of its obligations under this Agreement.

        (f) After the Effective Date and during Initial License Period, it is
        the intent of Incyte not to grant licenses to Third Parties in the
        diagnostic field of use under future Incyte database agreement(s) beyond
        the scope of that which has been previously granted by Incyte pursuant
        to Incyte database agreements in effect with Third Parties as of the
        Effective Date and further provided that after the Effective Date and
        during the Initial License Period it is the intent of Incyte to use
        commercially reasonable efforts to grant licenses to Third Parties in
        the diagnostic field of use under future Incyte database agreement(s)
        which are more restrictive in the field of Class III Tests.

    17.2  Compliance with Law. Each Party represents and warrants that it shall
        comply with all applicable laws, regulations and guidelines in
        connection with that Party's performance of its obligations and rights
        pursuant to this Agreement. Without limiting the generality of the
        foregoing, each Party shall be responsible for compliance with all
        applicable product safety, product testing, product labeling, package
        marking, and

                                       59
<PAGE>   59
     product advertising laws and regulations with respect to its own
     activities and products. Further, the Parties shall each comply with
     regulations of the United States and any other relevant nation concerning
     any export or other transfer of technology, services, or products.

17.3   Disclaimers.

     (a) NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE
     OR WARRANTY GIVEN BY A PARTY THAT ANY PATENT WILL ISSUE BASED UPON ANY
     PENDING PATENT APPLICATION, THAT ANY PATENT THAT HAS ISSUED OR IF IT
     ISSUES WILL BE VALID, OR THAT THE USE OF ANY LICENSE GRANTED HEREUNDER OR
     THAT THE USE OF ANY PATENT RIGHTS GRANTED HEREUNDER WILL NOT INFRINGE THE
     PATENT OR PROPRIETARY RIGHTS OF ANY OTHER PERSON. THE PARTIES MAKE NO
     REPRESENTATIONS OR WARRANTIES WITH RESPECT TO DIADEXUS'S USE OF THE
     INFORMATION TO BE PROVIDED TO IT HEREUNDER. EXCEPT AS EXPLICITLY STATED
     HEREIN, ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF
     MERCHANTABILITY, NOVELTY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR
     NON-INFRINGEMENT, ARE EXCLUDED. NO PARTY MAKES ANY WARRANTY THAT
     INFORMATION PROVIDED HEREUNDER DOES NOT CONTAIN ERRORS.

     (b) EXCEPT AS EXPLICITLY STATED HEREIN NO PARTY WILL BE LIABLE FOR
     CONSEQUENTIAL OR INCIDENTAL DAMAGES OF ANY NATURE ARISING FROM SUCH
     PARTY'S ACTIVITIES UNDER THIS AGREEMENT; PROVIDED, HOWEVER, THAT THIS
     LIMITATION SHALL NOT LIMIT THE INDEMNIFICATION OBLIGATION OF SUCH PARTY
     UNDER SECTION 18 BELOW FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES RECOVERED
     BY A THIRD PARTY.

                                18.0 INDEMNITY.

18.1  Direct Indemnity. Each Party shall indemnify and hold the other Parties
     harmless, and hereby forever releases and discharges the other Parties,
     from and against all losses, liabilities, damages and expenses (including
     attorney's fees and costs) arising out of a breach of the indemnifying
     Party's warranties or out of the negligence, recklessness or intentional
     misconduct of the indemnifying Party or its Affiliates in connection with
     activities under this Agreement except to the extent such losses,
     liabilities, damages and expenses (including attorney's fees and costs)
     resulted from the recklessness or intentional misconduct of the other
     Party or Parties.

                                       60

<PAGE>   60
     DiaDexus acknowledges and agrees that with respect to the nature of
     Incyte's and SB's Diagnostic IP and Technology IP, there can be no
     adequate remedy at law for any breach of DiaDexus obligations under the
     security provisions of this Agreement, that any such breach may result in
     irreparable harm to Incyte or SB, as the case may be, and therefore, that
     upon any such breach Incyte or SB, as the case may be, shall be entitled
     to appropriate equitable relief in addition to whatever remedies it might
     have at law, including injunctive relief, specific performance or such
     other relief as Incyte or SB, as the case may be, may request to enjoin or
     otherwise restrain any act prohibited hereby, as well as the recovery of
     all costs and expenses, including attorney's fees incurred. Incyte or SB,
     as the case may be, shall be entitled to indemnification by DiaDexus from
     any losses, liabilities, damages and expenses (including attorney's fees
     and costs), in connection with such unauthorized use or release of
     Confidential Information of Incyte or SB as the case may be.

18.2     Other Indemnity.  Except as otherwise provided below, each Party agrees
     to indemnify and hold the other Parties and its Affiliates harmless from
     and against any losses, damages and expenses (including attorney's fees
     and costs) suffered or incurred, and claims made, in connection with Third
     Party claims, demands, actions or other proceedings for personal injuries
     or any Product(s) recall to the extent caused by: (a) any and all uses or
     other disposition of Gene Product(s) or Product(s) or Ix Products by the
     indemnifying Party or its Affiliates, licensees, or sublicensees (other
     than the other Parties), (b) any failure to test for or provide adequate
     warnings of adverse side effects to the extent such failure arises out of
     acts or omissions in connection with a Party's or its Affiliates',
     licensees', or sublicensees' (other than the other Parties), preclinical
     or clinical testing or marketing of Gene Product(s) or Product(s) or Ix
     Products contemplated hereunder, (c) any manufacturing defect in any
     product or other material manufactured by a Party or its Affiliates,
     licensees, or sublicensees (other than the other Party), or (d) any other
     act or omission of  Party or its Affiliates, licensees, or sublicensees
     (other than the other Party), in connection with the activities
     contemplated under this Agreement, except to the extent such losses,
     liabilities, damages and expenses (including attorney's fees and costs)
     resulted from, recklessness or intentional misconduct of another Party.

18.3     Procedure.  A Party (the "Indemnitee") that intends to claim
     indemnification under this Section 18 shall promptly notify the other
     Party or Parties (the "Indemnitor") of any loss, liability, damage,
     expense, claim, demand, action or other proceeding in respect of which the
     Indemnitee or any of its Affiliates intend to claim such indemnification,
     and the Indemnitor shall have the right to participate in, and, to the
     extent the Indemnitor so desires, jointly with any other Indemnitor
     similarly noticed, to assume the defense thereof with counsel selected by
     the Indemnitor and reasonably satisfactory to the Indemnitee; provided,
     however, that an Indemnitee shall have the right to retain its own
     counsel, with the fees and expenses to be paid by the Indemnitee, if
     representation of such Indemnitee by the counsel retained by the
     Indemnitor would be inappropriate due

                                       61
<PAGE>   61
     to actual or potential differing interests between such Indemnitee and any
     other Party represented by such counsel in such proceedings. The indemnity
     agreement in this Section 18 shall not apply to amounts paid in settlement
     of any loss, liability, damage, expense, claim, demand, action or other
     proceeding if such settlement is effected without the consent of the
     Indemnitor, which consent shall not be withheld unreasonably. The failure
     to deliver notice to the Indemnitor within a reasonable time after the
     commencement of any such action, if prejudicial to its ability to defend
     such action, shall relieve such Indemnitor of any liability to the
     Indemnitee under this Section 18, but the omission so to deliver notice to
     the Indemnitor will not relieve it of any liability that it may have to any
     Indemnitee otherwise than under this Section 18. The Indemnitor may not
     settle the action or otherwise consent to an adverse judgment in action or
     other proceeding that materially diminishes the rights or interests of the
     Indemnitee without the express written consent of the Indemnitee. The
     Indemnitee under this Section 18 and its employee and agents, shall
     cooperate fully with the Indemnitor and its legal representatives in the
     investigation of any action, claim or liability covered by this
     indemnification.

                        19.0  MISCELLANEOUS PROVISIONS.

19.1 No Party shall incur any debts or make any commitments for the other,
except to the extent, if at all, specifically provided herein.

19.2 Assignment: This Agreement shall be binding upon and inure to the benefit
of the successors in interest of the respective parties. Subject to Paragraph
19.18, neither this Agreement nor any interest hereunder shall be assignable
directly or indirectly assigned or transferred (whether voluntarily, by
operation of law or otherwise) by any party without the prior express written
consent of the other parties; provided, however, that either Incyte or SB may
assign or transfer this Agreement or any of its rights or obligations hereunder
(i) to any Incyte Affiliate or SB Affiliate, respectively, or (ii) to the
extent assignment or transfer is deemed to occur as part of a Change of Control
(as such term is defined in the Master Strategic Relationship Agreement between
and among SB Corp, Incyte, and DiaDexus entered into of even date herewith), or
(iii) to any Third Party with which it may merge or consolidate, or to which it
may transfer all or substantially all of its assets to which this Agreement
relates, in each case without obtaining the consent of the other party, and if
in any such event (including any merger involving Incyte or SB), (i) (A) the
assigning party remains liable under this Agreement, and (ii) (B) the relevant
SB Affiliate or Incyte Affiliate assignee, Third Party assignee or surviving
entity assumes in writing all of the assigning party's obligations under this
Agreement. Any purported assignment or transfer in violation of this Paragraph
shall be void.

19.3 Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary
or appropriate in order to carry out the purposes and intent of this Agreement.

                                       62
<PAGE>   62

19.4  No Trademark Rights. Except as otherwise provided herein, no right,
      express or implied, is granted by this Agreement to use in any manner the
      names "Incyte", "SB", or "DiaDexus", or any other trade name or trademark
      of Incyte, SB or DiaDexus or their Affiliates.

19.5  Public Announcements. Notwithstanding Section 12, no Party shall make any
      public announcements or issue any press release concerning any aspect of
      the business, the relationship of the parties pursuant to this Agreement
      or any other matter incidental to the foregoing including any
      announcement that references the name of another party except (i) any
      disclosure that has been agreed to by the parties, including routine or
      recurring disclosures of agreed upon statements: (ii) disclosures
      required by applicable law so long as the text of any such disclosure is
      provided to the other parties for comment and review at least five (5)
      business days in advance of disclosure; and (iii) disclosures of material
      financial information in a press release that relates to a party's
      earnings or financial performance, so long as the text of any such
      disclosure is provided to the other parties for comment and review at
      least one (1) business day (business day) in advance of disclosure.

19.6  Entire Agreement of the Parties; Amendments. This Agreement constitutes
      and contains the entire understanding and agreement of the Parties and
      cancels and supersedes any and all prior negotiations, correspondence,
      representations, understandings and agreements, whether verbal or
      written, between the Parties respecting the subject matter hereof. No
      waiver, modification or amendment of any provision of this Agreement
      shall be valid or effective unless made in writing and signed by a duly
      authorized officer of each of the Parties.

19.7  Severability. In the event any one or more of the provisions of this
      Agreement shall for any reason be held by any court or authority having
      jurisdiction over this Agreement or any of the Parties to be invalid,
      illegal or unenforceable, such provision or provisions shall be validly
      reformed to as nearly as possible approximate the intent of the Parties
      and, if unreformable, shall be divisible and deleted in such
      jurisdiction; elsewhere, this Agreement shall not be affected so long as
      the Parties are still able to realize the principal benefits bargained
      for in this Agreement.

19.8  Captions. The captions to this Agreement are for convenience only, and
      are to be of no force or effect in construing or interpreting any of the
      provisions of this Agreement.

19.9  Applicable Law. This Agreement shall be governed by and interpreted in
      accordance with the laws of the State of California, without reference to
      the conflicts of law principles thereof.

                                       63
<PAGE>   63

19.10 Notices and Deliveries. Any notice, requests, delivery, approval or
      consent required or permitted to be given under this Agreement shall be
      in writing and shall be deemed to have been sufficiently given if
      delivered in person, transmitted by commercial overnight courier, or
      transmitted by telex telegram or telecopy to the Party to whom it is
      directed as its address shown below or such other address as such Party
      shall have last given by notice to the other Party. All notices shall be
      effective upon receipt.

If to Incyte, addressed to:
      Incyte Pharmaceuticals, Inc.
      3174 Porter Drive
      Palo Alto, CA 94304
      Attn: Roy Whitfield, CEO
      Tel: (415)-855-0555
      Fax: (415)-855-0572

If to DiaDexus, addressed to:
      diaDexus
      3233 Scott Boulevard
      Suite 102
      Santa Clara, CA 95054
      Attention: Patrick Plewman
      Vice President Corporate Development
      Tel: (415)-
      Fax: (415)-

If to SB, addressed to:
      SmithklineBeecham Corporation
      709 Swedeland Road
      King of Prussia, Pennsylvania 19103
      Attention: Director,
      Alliance and Technology Group
      SmithKline Beecham Pharmaceuticals
      Tel: (610)-270-5973
      Fax: (610)-270-5962

      copy to:    SMITHKLINE BEECHAM CORPORATION
                  709 Swedeland Road
                  P.O. Box 1539
                  King of Prussia, Pennsylvania 19406
                    Attention: Corporate Law
                  Tel: (610)-270-5031
                  Fax: (610)-270-4026

                                       64
<PAGE>   64
19.11 Counterparts. This Agreement may be executed in two or more counterparts,
      each of which shall be deemed an original, but all of which together
      shall constitute one and the same instrument.

19.12 Force Majeure. Force Majeure shall mean an Act of God, flood, fire,
      explosion, earthquake, strike, lockout, casualty or accident, war, civil
      commotion, act of public enemies, blockage or embargo, or any injunction,
      law, order, proclamation, regulation, ordinance, demand or requirement of
      any government or any subdivision, authority representative thereof, or
      any other cause whatsoever, whether similar or dissimilar to those
      enumerated above, which are beyond the reasonable control of such Party,
      which the Party affected has used its reasonable best efforts to avoid,
      and which prevent, restrict or interfere with the performance by a Party
      of its obligations hereunder. The Party affected by Force Majeure shall
      give notice to the other Party promptly in writing and whereupon shall be
      excused from those obligations hereunder, to the extent of such
      prevention, restriction or interference, provided that the affected Party
      shall use its commercially reasonable efforts to avoid or remove such
      cause(s) of non-performance and shall continue performance whenever such
      cause(s) is removed.

19.13 Affiliate Performance. To the extent that any Affiliate of DiaDexus has
      the right to receive any other rights or benefits under this Agreement or
      otherwise is obligated to perform any obligations under this Agreement,
      DiaDexus shall cause such Affiliate to perform in full, when due, all
      applicable obligations under this Agreement to the same extent as if such
      Affiliate were a Party to this Agreement; provided, however, that nothing
      in this Paragraph 19.13 shall expand the rights or benefits of DiaDexus
      or its Affiliates, or the obligations of Incyte, or SB beyond those
      otherwise expressly set forth in this Agreement. DiaDexus shall guaranty
      timely performance in full by such Affiliate of all such obligations. A
      breach by such Affiliate of any such obligation shall constitute a breach
      by DiaDexus of this Agreement and shall entitle Incyte or SB to exercise
      its rights under Section 16.0 (Term and Termination) above, in addition
      to any other rights and remedies to which Incyte and/or SB may be
      entitled.

19.14 Recording. Any Party shall have the right, at any time, to record,
      register, or otherwise notify this Agreement in appropriate governmental
      or regulatory offices anywhere in the world, and the other parties shall
      provide reasonable assistance to the notifying Party in effecting such
      recording, registering or notifying.

19.15 Dispute Resolution. (a) Any controversy or claim arising out of or
      relating to this Agreement, or the breach thereof or misrepresentation
      thereunder including any disputes regarding rights of the parties to
      terminate this Agreement, or whether any such termination has been
      wrongfully undertaken, shall first be submitted for resolution to a
      committee consisting of the chief executive officer of each of the
      parties involved in such dispute, whether they include SB and Incyte or
      DiaDexus and either of SB and Incyte, or any combination of the
      foregoing. If the committee is

                                       65
<PAGE>   65
      unable to resolve such controversy or claim within twenty (20) days of the
      submission of such matter to the committee, then the parties may have
      access to any remedies available under applicable law or otherwise.

        (b)   The parties agree that termination of this Agreement shall be
      available in accordance with the terms of this Agreement, but it is the
      intention of the Parties that disputes shall be resolved without
      termination of this Agreement to the maximum extent possible.

19.16 No Partnership. Nothing in this Agreement is intended or shall be deemed
      to constitute a partnership, agency, distributorship, employer-employee or
      joint venture relationship between the Parties. No Party shall incur any
      debts or make any commitments for the other, except to the extent, if at
      all, specifically provided herein.

19.17 No Implied Licenses. No implied right or license is granted to any Party
      to utilize another's intellectual property in a manner not expressly
      included within the scope of the licenses granted pursuant to this
      Agreement. Other than as expressly granted herein, no licenses either by
      estoppel, implication or otherwise are granted herein.

19.18 Certain Research Commitments.

        (a)   During the Initial License Period, unless this Agreement has been
      terminated pursuant to Paragraph 16.2 or 16.3, Incyte shall not materially
      reduce the intellectual property that would otherwise have been available
      as Incyte Technology IP and Incyte Diagnostic IP pursuant to Sections 3
      and 9 of this Agreement by way of assignment of its rights or obligations
      as permitted under Paragraph 19.2.

        (b)   During the Initial License Period, unless this Agreement has been
      terminated pursuant to Paragraph 16.2 or 16.3, (1) prior to the occurrence
      of a Change of Control (as such term is defined in the Master Strategic
      Relationship Agreement between and among SB Corp, Incyte, and DiaDexus
      entered into of even date herewith) with respect to SB, SB shall not
      materially reduce the intellectual property that would otherwise have been
      available as SB Technology IP and SB Diagnostic IP pursuant to Sections 4
      and 9 of this Agreement by way of assignment of its rights or obligations
      as permitted under Paragraph 19.2; and (2) after the occurrence of a
      Change of Control with respect to SB, SB shall perform ethical
      pharmaceuticals research and development in entities which are subject to
      Sections 4 and 9 at an aggregate level of at least US $700 Million Dollars
      per annum.

                                       66
<PAGE>   66
   IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this Agreement as of the date first written above.

SmithKline Beecham Corporation

By: [SIGNATURE ILLEGIBLE]
   ---------------------------

SmithKline Beecham, plc

By: [SIGNATURE ILLEGIBLE]
   ---------------------------

Incyte Pharmaceuticals, Inc.

By: [SIGNATURE ILLEGIBLE]
   ---------------------------

diaDexus, LLC

By: /s/ P. PLEWMAN
   ---------------------------

                                       67
<PAGE>   67
                                   Appendix A
                                 HGS Agreements

Collaboration Agreement: effective as of the 19th day of May, 1993, between
Human Genome Sciences, Inc., a corporation organized under the laws of the
State of Delaware, having a place of business at 9620 Medical Center Drive,
Rockville, Maryland 20850, U.S.A. and SmithKline Beecham Corporation, a
corporation organized under the laws of the Commonwealth of Pennsylvania,
United States of America, having a principal place of business at One Franklin
Plaza, Philadelphia, Pennsylvania 19101, U.S.A.

Amended and Restated License Agreement: effective as of the 31st day of May,
1995, between Human Genome Sciences, Inc., a corporation organized under the
laws of the State of Delaware, having a place of business at 9410 Key West
Avenue, Rockville, Maryland 20850, U.S.A. ("HGS"), SmithKline Beecham
Corporation, a corporation organized under the laws of the Commonwealth of
Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia,
Pennsylvania 19101, U.S.A. ("SB corp"), and SmithKline Beecham Intercredit,
B.V., a corporation organized under the laws of the Netherlands and having a
place of business at Jaagpad 1, 2280 GC Hijswijk, the Netherlands ("SBI"), and
their AFFILIATES (individually and collectively "SB").

SB/HGS License Agreement: effective as of the 28th day of June, 1996 between,
on the one hand, SmithKline Beecham Corporation, a corporation organized under
the laws of the Commonwealth of Pennsylvania, having a place of business at One
Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. ("SB corp"),
SmithKline Beecham p.l.c., a corporation organized under the laws of England
and having a place of business at Great West Road, Brentford, Middlesex, U.K.
("SB p.l.c.") (individually and collectively "SB"), and, on the other hand,
Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, Maryland 20850
("HGS").

Merck/SB/HGS
Collaboration And License Agreement: effective as of the 10th day of July, 1996
by and among SmithKline Beecham Corporation, a corporation organized under the
laws of the Commonwealth of Pennsylvania, having a place of business at One
Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. ("SB corp"),
SmithKline Beecham p.l.c., a corporation organized under the laws of England
and having a place of business at Great West Road, Brentford, Middlesex,
England ("SB plc") (individually and collectively "SB"), Human Genome
Sciences, Inc. located at 9410 Key West Avenue, Rockville, Maryland 20850
("HGS") and Merck KGaA, Frankfurter Str. 250, 64271 Darmstadt, Germany
("Merck").

Therapeutic Collaboration And License Agreement: effective as of the 28th of
June, 1996 by and among Human Genome Sciences, Inc., a corporation organized
under the laws of the State of Delaware, United States of America, having a
place of business at 9410 Key West Avenue, Rockville, Maryland 20850, for
itself and its Affiliates, as defined below (collectively including such
Affiliates "HGS"), Schering Corporation, a corporation organized under the laws
of the State of New Jersey, United States of America, having a place of
business at 2000 Galloping Hill Road,

                                       68
<PAGE>   68
Kenilworth, New Jersey 07033, and Schering Plough Ltd., a Swiss corporation
having its principal place of business at Toepferstrasse 5, CH-6004 Lucerne,
Switzerland, each for itself and its Affiliates, as defined below (collectively
including such Affiliates "SP"), and SmithKline Beecham Corporation, a
corporation organized under the laws of the Commonwealth of Pennsylvania,
United States of America, having a place of business at 709 Swedeland Road,
King of Prussia, Pennsylvania, 19406 and SmithKline Beecham, plc, having a
place of business at Great West Road, Brentford, Middlesex, U.K.

Synthelabo/SB/HGS
Collaboration And License Agreement: effective as of the 28th day of June, 1996
by and among SmithKline Beecham Corporation, a corporation organized under the
laws of the Commonwealth of Pennsylvania, having a place of business at One
Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. ("SB corp"),
SmithKline Beecham p.l.c., a corporation organized under the laws of England
and having a place of business at Great West Road, Brentford, Middlesex,
England ("SB plc") (individually and collectively "SB"), Human Genome Sciences,
Inc. located at 9410 Key West Avenue, Rockville, Maryland 20850 ("HGS") and
Synthelabo, located at 22, avenue Galilee, 92352 Le Plessis-Robinson Cedex
France ("Synthelabo").

Restated SB-Takeda Collaboration And License Agreement: effective as of the
28th day of June 1996 between, on the one hand, SmithKline Beecham Corporation,
a corporation organized under the laws of the Commonwealth of Pennsylvania,
having a place of business at One Franklin Plaza, Philadelphia, Pennsylvania
19101, U.S.A. ("SB corp"), SmithKline Beecham p.l.c., a corporation organized
under the laws of England and having a place of business at Great West Road,
Brentford, Middlesex, U.K. ("SB p.l.c."), (individually and collectively "SB"),
and, on the other hand, Takeda Chemical Industries, Ltd., a corporation
organized under the laws of Japan, having a principal place of business at 1-1,
Doshomachi 4-Chome, Chuo-ku, Osaka, 541, Japan, and its Affiliates ("TAKEDA").

SB/HGS DIAGNOSTIC LICENSE AGREEMENT effective July, 1997 between, on the one
hand, SmithKline Beecham Corporation, a corporation organized under the laws of
the Commonwealth of Pennsylvania, having a place of business at One Franklin
Plaza, Philadelphia, Pennsylvania 19101, U.S.A. ("SB corp"), SmithKline Beecham
p.l.c., a corporation organized under the laws of England and having a place of
business at Great West Road, Brentford, Middlesex, U.K. ("SB p.l.c."),
(individually and collectively "SB"), and, on the other hand, Human Genome
Sciences, Inc., 9410 Key West Avenue, Rockville, Maryland 20850 ("HGS").

                                       69
<PAGE>   69
Appendix F

                          RESEARCH PROGRAM REPORT FORM

  I. BACKGROUND

     a.   briefly describe how diagnostic target/gene was identified

     b.   briefly describe data regarding potential diagnostic utility

 II. KEY MILESTONES

     a.   list key milestones and anticipated dates for achievement

     b.   describe current status of project relative to milestones and
          associated dates for accomplishments

III. CLINICAL EVALUATION

     a.   list clinical utility claims desired

     b.   briefly describe the studies needed for clinical evaluation

 IV. PATENT

     a.   list patents filed by DiaDexus relating to the diagnostic target/gene

                                       70

<PAGE>   70
                              APPENDIX G, II, I, J

          APPENDIX CONTENTS

          II.  SB DIAGNOSTIC PATENTS - COMMITTED

          1b.  SB DIAGNOSTIC PATENTS - ON OFFER

          G.   SB DIAGNOSTIC KNOW HOW - COMMITTED

          IIb. SB DIAGNOSTIC KNOW HOW - ON OFFER

          I.   SB TECHNOLOGY KNOW HOW

          J.   SB TECHNOLOGY PATENTS

<PAGE>   71

                      II. SB DIAGNOSTIC PATENTS - COMMITTED

<TABLE>
<CAPTION>
                                                            SUBJECT/
DOCKET NO.                    TITLE                         DESCRIPTION    SERIAL NO
----------                    -----                         -----------    ---------
<S>                 <C>                                     <C>            <C>
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****
*****               *****
*****               *****                                                  *****          HGS
*****               *****                                                  *****          HGS
*****               *****                                                  *****
*****               *****                                                  *****
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   72

<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               *****                                                  *****
*****               *****
*****               *****                                                  *****
*****               *****                                                  *****
*****               *****
*****               *****
*****               *****
*****               *****                                                                 ***
*****               *****
*****               *****

*****               *****
*****               *****
*****               *****
*****               *****
*****               *****
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   73

<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
                    *****
*****               Novel COMPOUNDS
*****               Novel COMPOUNDS
*****               Novel COMPOUNDS*****                    *****
*****               Novel COMPOUNDS*****                    *****
*****               *****
*****               Novel Compounds*****                    *****
*****               Novel Compounds*****                    *****
*****               Novel Compounds*****                    *****
*****               Novel Compounds*****                    *****
*****               Novel*****
*****               *****
*****               Novel*****
*****               Novel Compounds*****                    *****
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   74

<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
                                                            *****
*****               Novel Compounds*****                    *****
*****               Novel Compounds(-"-)                    *****
                    Novel*****                              *****
*****               Novel*****                              *****
*****               Novel COMPOUNDS                         *****
*****               Novel COMPOUNDS                         *****
*****               *****                                   *****
*****               *****                                   *****
*****               *****                                   *****
</TABLE>

***** Certain information on this page and all of the information on the next
      three pages have been omitted and filed separately with the Securities and
      Exchange Commission. Confidential treatment has been requested with
      respect to the omitted portions.
<PAGE>   75

<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               *****
*****               *****
*****               *****
*****               *****
*****               *****
*****               *****
*****               *****                                   ******
*****               Novel*****
*****               Novel*****
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   76

<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               Novel*****
*****               NOVEL*****
*****               NOVEL*****
*****               Novel*****
*****
*****
*****
*****
*****
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL*****
*****               NOVEL COMPOUNDS
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   77
<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   78
<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   79
<TABLE>
<CAPTION>
<S>                 <C>                                     <C>            <C>            <C>
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               NOVEL COMPOUNDS
*****               *****
                    *****                                                  *****
</TABLE>

***** Certain information on this page and all of the information on the next
      three pages have been omitted and filed separately with the Securities and
      Exchange Commission. Confidential treatment has been requested with
      respect to the omitted portions.
<PAGE>   80

                    II. SB DIAGNOSTIC TECHNOLOGY - COMMITTED

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: ******                   MOST RECENT UPDATE: ******

1.   BACKGROUND
     a.   TARGET IDENTIFICATION ******

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          ******

2.   KEY MILESTONES
     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT
          1) ******
          2) ******
          3) ******

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   81

3.   CLINICAL EVALUATION
     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          ******

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          ******

4.   PATENT STATUS

          ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   82

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: ******                   MOST RECENT UPDATE: ******

1.   BACKGROUND
     a.   TARGET IDENTIFICATION ******

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          ******

2.   KEY MILESTONES
     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT
          1) ******
          2) ******
          3) ******
          4) ******

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   83

3.   CLINICAL EVALUATION
     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          ******

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          ******

4.   PATENT STATUS

          ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   84

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: ******                   MOST RECENT UPDATE: ******

1.   BACKGROUND
     a.   TARGET IDENTIFICATION ******

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          ******

2.   KEY MILESTONES
     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT
          1) ******
          2) ******
          3) ******

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          ******

***** Certain information on this page has been omitted and filed separately
      with the securities and exchange commission. confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   85

3.   CLINICAL EVALUATION
     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          ******

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          ******

     PATENT STATUS

          ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   86
                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *******                     MOST RECENT UPDATE: ******

1. BACKGROUND

   a. TARGET IDENTIFICATION *******

   b. BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY
      *******

2. KEY MILESTONES

   a. LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

      1) *****
      2) *******
      3) *******

   b. DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND ASSOCIATED
      DATES FOR ACCOMPLISHMENT.

         ********

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   87
3. CLINICAL EVALUATION

   a. LIST CLINICAL UTILITY CLAIMS DESIRED.
      *******

   b. BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND STATUS OF
      THOSE STUDIES.
      *******

4. PATENT STATUS
      *******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   88
                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: ******                      MOST RECENT UPDATE: ******

1. BACKGROUND

   a. TARGET IDENTIFICATION ********

   b. *******

2. KEY MILESTONES

   a. LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

      1) *******
      2) *******
      3) ********

   b. DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND ASSOCIATED
      DATES FOR ACCOMPLISHMENT.

         *******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   89
3. CLINICAL EVALUATION

   a. LIST CLINICAL UTILITY CLAIMS DESIRED
      ********

   b. BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND STATUS OF
      THOSE STUDIES.
      *******

4. PATENT STATUS

   *******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   90
                     IIb. SB DIAGNOSTIC TECHNOLOGY-ON OFFER

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: ******              MOST RECENT UPDATE: ******

1.   BACKGROUND

     a.   TARGET IDENTIFICATION ******

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

              ******

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   ******

          2)   ******

          3)   ******

          4)   ******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   91
     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

             *******

3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

             *******

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND STATUS
          OF THOSE STUDIES.

             *******

4.   PATENT STATUS

             *******

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   92

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                     MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   93
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   94

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   95
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   96

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   97
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   98

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   99
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   100

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   101
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   102

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   103
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   104

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   105
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   106

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   107
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   108

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   109
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   110
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   111

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   112
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   113

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   114
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   115

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   116
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   117

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   118
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   119

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   120
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   121

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)

          2)   *****

          3)

          4)

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   122
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   123

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   124
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   125

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   126
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   127

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   128
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   129

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   130
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   131

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   132
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   133

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   134
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   135

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   136
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   137

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   138
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   139

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   140
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   141

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   142
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED.

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   143

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   144
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   145

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   146
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   147

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   148
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   149

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   150
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   151

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   152
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   153

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   154
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   155

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   156
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   157

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   158
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   159

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   160
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   161

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   162
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   163

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                   MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   164
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   165

                          RESEARCH PLAN FOR DIAGNOSTIC

PROPOSED DIAGNOSTIC FOR: *****                    MOST RECENT UPDATE: *****

1.   BACKGROUND

     a.   TARGET IDENTIFICATION  *****

     b.   BRIEF DESCRIPTION OF DATA REGARDING POTENTIAL DIAGNOSTIC UTILITY

          *****

2.   KEY MILESTONES

     a.   LIST KEY MILESTONES AND ANTICIPATED DATES FOR ACHIEVEMENT

          1)   *****

          2)   *****

          3)   *****

          4)   *****

     b.   DESCRIBE CURRENT STATUS OF PROJECT RELATIVE TO MILESTONES AND
          ASSOCIATED DATES FOR ACCOMPLISHMENT.

          *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   166
3.   CLINICAL EVALUATION

     a.   LIST CLINICAL UTILITY CLAIMS DESIRED

          *****

     b.   BRIEFLY DESCRIBE THE STUDIES NEEDED FOR CLINICAL EVALUATION AND
          STATUS OF THOSE STUDIES.

          *****

4.   PATENT STATUS

     *****

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   167
                           I. SB TECHNOLOGY KNOW HOW

          SB Technology Know How associated with SB Technology Patents
<PAGE>   168

                                   Appendix C
                           INCYTE DIAGNOSTIC PATENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
COUNTRY                   REFERENCES     TYPE     FILED      SERIAL #     ISSUED     PATENTS    STATUS
------------------------------------------------------------------------------------------------------------
<S>                      <C>             <C>      <C>        <C>          <C>        <C>        <C>
AUSTRALIA                   ******       ****     3/1/93     ********     12/19/95    *******   ISSUED
CANADA                      ******       ****     7/9/91     ********                           PENDING
CANADA                      ******       ****     3/10/93    ********                           PENDING
EUROPEAN PATENT CO          ******       ****     7/9/91     ********                           PENDING
EUROPEAN PATENT CO          ******       ****     3/10/93    ********                           PENDING
JAPAN                       ******       ****     7/9/91     ********                           PENDING
UNITED STATES               ******       ****     7/10/90    ********                           ABANDONED
UNITED STATES               ******       ****     9/11/92    ********                           ABANDONED
UNITED STATES               ******       ****     12/18/95   ********                           PENDING
UNITED STATES               ******       ****     2/28/95    ********                           ABANDONED
UNITED STATES               ******       ****     6/15/94    ********     11/28/95   ********   ISSUED
UNITED STATES               ******       ****     5/19/94    ********     12/19/95     ******   ISSUED
WIPO                        ******       ****     7/9/91     ********                           PENDING
WIPO                        ******       ****     7/8/91     ********                           ABANDONED
WIPO                        ******       ****     9/10/93    ********                           PENDING
------------------------------------------------------------------------------------------------------------
AUSTRALIA                   ******       ****     10/31/90   ********                           ABANDONED
[TEXT ILLEGIBLE]            ******       ****     10/31/90   ********                           PENDING
EUROPEAN PATENT CO          ******       ****     10/31/90   ********                           PENDING
UNITED STATES               ******       ****     11/3/89    ********                           ABANDONED
UNITED STATES               ******       ****     7/11/92    ********                           PENDING
UNITED STATES               ******       ****     8/12/92    ********                           ABANDONED
UNITED STATES               ******       ****     8/12/92    ********                           ABANDONED
WIPO                        ******       ****     10/31/90   ********                           PUBLISHED
------------------------------------------------------------------------------------------------------------
UNITED STATES                *****       ****     12/10/90      *****                           ABANDONED
UNITED STATES                *****       ****     4/22/94       *****                           PENDING
UNITED STATES                *****       ****     4/24/95       *****                           ABANDONED
------------------------------------------------------------------------------------------------------------
AUSTRIA                     ******       *****    5/25/89    ********     7/20/94         ***   ISSUED
AUSTRALIA                   ******       *****    5/26/89    ********     6/4/93          ***   ISSUED
BELGIUM                     ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
CANADA                      ******       *****    4/25/89    ********                           PENDING
SWITZERLAND                 ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
GERMANY                     ******       *****    5/26/89    ********     7/20/94    ********   ISSUED
EUROPEAN PATENT CO          ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
FRANCE                      ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
UNITED KINGDOM              ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
ITALY                       ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
JAPAN                       ******       *****    5/26/89    ********                           PENDING
LUXEMBOURG                  ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
NETHERLANDS                 ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
SWEDEN                      ******       *****    5/26/89    ********     7/20/94         ***   ISSUED
UNITED STATES               ******       *****    5/26/89    ********     7/16/91         ***   ISSUED
UNITED STATES               ******       *****    7/15/91    ********     5/11/93         ***   ISSUED
UNITED STATES               ******       *****    5/10/93    ********                           ABANDONED
WIPO                        ******       *****    5/26/89    ********                           PENDING
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.
<PAGE>   169

**************

<TABLE>
------------------------------------------------------------------------------------------------------------
<S>                      <C>             <C>      <C>        <C>          <C>        <C>        <C>
AUSTRALIA                  *****          **     2/14/90     *****        7/19/94    *****      ISSUED
AUSTRALIA                  *****          **     8/12/91     *****        6/29/95    *****      ISSUED
AUSTRALIA                  *****          **     8/28/92     *****        2/27/98    *****      ISSUED
AUSTRALIA                  *****          **     7/1/94      *****                              PENDING
AUSTRALIA                  *****          **     4/29/94     *****                              PENDING
CANADA                     *****          **     2/14/90     *****                              PENDING
CANADA                     *****          **     8/13/91     *****                              PENDING
CANADA                     *****          **     8/29/92     *****                              PENDING
CANADA                     *****          **     7/1/94      *****                              PENDING
CANADA                     *****          **     4/29/94     *****                              PENDING
EUROPEAN PATENT CO         *****          **     2/14/90     *****                              PENDING
EUROPEAN PATENT CO         *****          **     8/13/91     *****                              PENDING
EUROPEAN PATENT CO         *****          **     9/28/92     *****                              PENDING
EUROPEAN PATENT CO         *****          **     7/1/94      *****                              PUBLISHED
EUROPEAN PATENT CO         *****          **     4/29/94     *****                              PENDING
ISRAEL                     *****          **     2/12/90     *****                              PENDING
JAPAN                      *****          **     2/14/90     *****                              PENDING
JAPAN                      *****          **     8/13/91     *****                              PENDING
JAPAN                      *****          **     9/28/92     *****                              PENDING
JAPAN                      *****          **     7/1/94      *****                              PENDING
JAPAN                      *****          **     4/29/94     *****                              PENDING
SOUTH KOREA                *****          **     2/14/90     *****                              PENDING
SOUTH KOREA                *****          **     8/13/91     *****                              PENDING
NEW ZEALAND                *****          **     2/13/90     *****                              PENDING
UNITED STATES              *****          **     2/14/89     *****                              ABANDONED
UNITED STATES              *****          **     8/13/89     *****                              ABANDONED
UNITED STATES              *****          **     4/5/91      *****        12/15/92   *****      ISSUED
UNITED STATES              *****          **     7/3/91      *****                              ABANDONED
UNITED STATES              *****          **     5/21/93     *****                              ABANDONED
UNITED STATES              *****          **     7/22/92     *****                              PENDING
UNITED STATES              *****          **     7/2/93      *****                              ABANDONED
UNITED STATES              *****          **     12/3/93     *****                              ABANDONED
UNITED STATES              *****          **     4/30/93     *****                              ABANDONED
UNITED STATES              *****          **     5/1/95      *****                              PENDING
UNITED STATES              *****          **     1/22/90     *****        12/18/92   *****      ISSUED
UNITED STATES              *****          **     12/14/92    *****        5/3/94     *****      ISSUED
UNITED STATES              *****          **     12/14/92    *****        8/2/94     *****      ISSUED
UNITED STATES              *****          **     9/27/91     *****        6/10/93    *****      ISSUED
UNITED STATES              *****          **     11/13/96    *****                              PENDING
UNITED STATES              *****          **     11/13/96    *****                              PENDING
UNITED STATES              *****          **     4/18/97     *****                              PENDING
WIPO                       *****          **     2/14/90     *****                              PENDING
WIPO                       *****          **     8/13/91     *****                              PENDING
WIPO                       *****          **     9/23/92     *****                              PENDING
WIPO                       *****          **     7/1/94      *****                              PENDING
WIPO                       *****          **     4/28/94     *****                              PENDING
WIPO                       *****          **     5/1/95      *****                              PENDING

14-BETA-GAL MAMMALIAN LECTINS
------------------------------------------------------------------------------------------------------------
AUSTRALIA                  *****          **     4/14/89     *****        5/11/93    *****      ISSUED
BELGIUM                    *****          **     4/14/89     *****        8/7/96     *****      ISSUED
CANADA                     *****          **     4/14/89     *****        1/28/97    *****      ISSUED
GERMANY                    *****          **     4/14/89     *****        8/7/96     *****      ISSUED
EUROPEAN PATENT CO         *****          **     4/14/89     *****        8/7/96     *****      ISSUED
SPAIN                      *****          **     4/14/89     *****        8/7/96     *****      ISSUED
FRANCE                     *****          **     4/14/89     *****        8/7/96     *****      ISSUED
UNITED KINGDOM             *****          **     4/14/89     *****        8/7/96     *****      ISSUED
GREECE                     *****          **     4/14/89     *****        8/7/96     *****      ISSUED
[TEXT ILLEGIBLE]           *****          **     4/14/89     *****        8/7/96     *****      ISSUED
[TEXT ILLEGIBLE]           *****          **     4/14/89     *****                              PENDING
LUXEMBOURG                 *****          **     4/14/89     *****        8/7/96     *****      ISSUED
NETHERLANDS                *****          **     4/14/89     *****        8/7/96     *****      ISSUED
SWEDEN                     *****          **     4/14/89     *****        8/7/96     *****      ISSUED
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   170

<TABLE>
------------------------------------------------------------------------------------------------------------
<S>                      <C>             <C>      <C>        <C>          <C>        <C>        <C>
UNITED STATES              *****          **     4/14/88     *****                              ABANDONED
UNITED STATES              *****          **     10/28/88    *****                              PENDING
UNITED STATES              *****          **     2/21/89     *****                              ABANDONED
UNITED STATES              *****          **     11/16/92    *****                              ABANDONED
UNITED STATES              *****          **     10/20/94    *****                              PENDING
UNITED STATES              *****          **     8/26/96     *****                              PENDING
UNITED STATES              *****          **     8/5/94      *****        12/24/96   ****       ISSUED
UNITED STATES              *****          **     12/8/95     *****                   ****       ISSUED
UNITED STATES              *****          **     9/25/96     *****                              PENDING
UNITED STATES              *****          **     9/25/96     *****                              PENDING
UNITED STATES              *****          **     9/25/96     *****                              PENDING
WIPO                       *****          **     11/16/93    *****                              PENDING
------------------------------------------------------------------------------------------------------------
UNITED STATES              MF-0009 US     NEW    12/9/90     07/630,976                         PENDING
UNITED STATES              MF-0009-1 CIP  CIP    4/22/94     08/232,859                         PENDING

       ************
------------------------------------------------------------------------------------------------------------
UNITED STATES              *****          **     8/19/91     *****                              ABANDONED
UNITED STATES              *****          **     7/25/94     *****                              ABANDONED
UNITED STATES              *****          **     5/16/95     *****                              PENDING
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   171
                                   Appendix D

                           Incyte Technology Know-How

Included in this Appendix is all Incyte Technology Know-How associated with
Incyte Technology Patents.
<PAGE>   172
                                   Appendix E
                           INCYTE TECHNOLOGY PATENTS

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
COUNTRY                  REFERENCES          TYPE      FILED     SERIALS        ISSUED        PATENTS       STATUS
-------------------------------------------------------------------------------------------------------------------
<S>                      <C>                 <C>       <C>       <C>            <C>           <C>           <C>
                       **************
-------------------------------------------------------------------------------------------------------------------
[ILLEGIBLE]                *****             *****     1/27/95    *****                                     PENDING
AUSTRALIA                  *****             *****     1/27/95    *****                                     PENDING
BULGARIA                   *****             *****     1/27/95    *****                                     PENDING
BRAZIL                     *****             *****     1/27/95    *****                                     PENDING
CANADA                     *****             *****     1/27/95    *****                                     PENDING
CHINA                      *****             *****     1/27/95    *****                                     PENDING
CZECH REPUBLIC             *****             *****     1/27/95    *****                                     PENDING
ESTONIA                    *****             *****     1/27/95    *****                                     PUBLISHED
EUROPEAN PATENT CO.        *****             *****     1/27/95    *****                        *****        ISSUED
ENGLAND                    *****             *****     1/27/95    *****                                     PENDING
GEORGIA                    *****             *****     1/27/95    *****                                     PENDING
HUNGARY                    *****             *****     1/27/95    *****                                     ABANDONED
JAPAN                      *****             *****     1/27/95    *****                                     PENDING
NORTH KOREA                *****             *****     1/27/95    *****                                     PENDING
SOUTH KOREA                *****             *****     1/27/95    *****                                     PENDING
SRI LANKA                  *****             *****     1/27/95    *****                                     PENDING
[ILLEGIBLE]                *****             *****     1/27/95    *****                                     PENDING
MONGOLIA                   *****             *****     1/27/95    *****                                     PENDING
[ILLEGIBLE]                *****             *****     1/27/95    *****                                     PENDING
[ILLEGIBLE]                *****             *****     1/27/95    *****                                     PENDING
NEW ZEALAND                *****             *****     1/27/95    *****                                     PENDING
AFRICAN UNION              *****             *****     1/27/95    *****                                     PENDING
POLAND                     *****             *****     1/27/95    *****                                     PENDING
ROMANIA                    *****             *****     1/27/95    *****                                     PENDING
FEDERATION OF RUSSIA       *****             *****     1/27/95    *****                                     PENDING
UKRAINE                    *****             *****     1/27/95    *****                                     PENDING
UNITED STATES              *****             *****     1/27/94    *****                                     PENDING
UNITED STATES              *****             *****     7/28/94    *****                                     PENDING
VIETNAM                    *****             *****     1/27/95    *****                                     PENDING
WIPO                       *****             *****     1/27/95    *****                        *****        ISSUED

**************
-------------------------------------------------------------------------------------------------------------------
UNITED STATES            HP-0001 US          *****     6/7/85     *****                                     PENDING
UNITED STATES            HP-0001-1 US        *****     [ILLEG.]   *****                                     PENDING
WIPO                     HP-0001-1 PCT       *****     6/3/96     *****                                     PUBLISHED

**************
-------------------------------------------------------------------------------------------------------------------
AUSTRALIA                CM-0001 AU          *****     3/14/95    *****                                     PENDING
CANADA                   CM-0001 CA          *****     3/14/95    *****                                     PENDING
EUROPEAN PATENT CO       CM-0001 EP          *****     3/14/95    *****                                     PENDING
JAPAN                    CM-0001 JP          *****     3/14/95    *****                                     PENDING
MEXICO                   CM-0001 MX          *****     8/13/95    *****                                     PENDING
UNITED STATES            CM-0001 US          *****     3/16/94    *****                                     PENDING
WIPO                     CM-0001 PCT         *****     3/14/95    *****                                     PENDING

**************
-------------------------------------------------------------------------------------------------------------------
UNITED STATES            CM-0002 US          *****     5/17/96    *****                                     PENDING
WIPO                     CM-0002 PCT         *****     5/13/97    *****                                     PENDING

**************
-------------------------------------------------------------------------------------------------------------------
UNITED STATES            CM-0003 US          *****     9/16/96    *****                                     PENDING

**************
-------------------------------------------------------------------------------------------------------------------
UNITED STATES            CM-0004 US          *****     12/13/96   *****                                     PENDING
</TABLE>

***** Certain information on this page has been omitted and filed separately
      with the Securities and Exchange Commission. Confidential treatment has
      been requested with respect to the omitted portions.

<PAGE>   173
                                Schedule 1.1(a)

<TABLE>
<CAPTION>
SB R&D - Upper Merion, USA

                                          Date         Dep       Asset     Accum               YTD
Description                             Acquired       Met       Cost      Degree     NBV      Deprec
--------------------------------------------------------------------------------------------------------
<S>                                     <C>            <C>       <C>       <C>        <C>      <C>
B05911 Optical Storage                  6/25/96        01         1,781       -292     1,489       .94
B05912 Optical Storage                  6/25/96        01           445        -73       372       .24
B07461 Imaging System                   6/25/96        01        84,123    -10,212    73,911    -4,689
B07555 Freezer - Liquid Nitrogen        6/25/96        01        12,432     -1,513    10,919      -693
F08060 Illuminator TM15 Transill        6/25/96        01           777       -227       550       -39
F08061 Misc Lab Equipment               6/25/96        01           988       -289       699       -50
F08074 Centrifuge                       6/25/96        01         1,590       -658       922       -66
F08075 Incubator                        6/25/96        01         4,034     -1,181     2,853      -204
F08124 Freezer                          6/25/96        01           854       -250       604       -43
F41277 Centrifuge                       6/25/96        01         8,125     -3,306     4,520      -394
F41835 Electrophoresis Unit             6/25/96        01         6,255     -2,467     3,798      -311
F41837 Incubator                        6/25/96        01        20,391     -8,029    12,362    -1,011
F41838 Vacuum                           6/25/96        01         3,215     -1,256     1,949      -159
F41866 Centrifuge                       6/25/96        01         2,727     -1,095     1,631      -133
F41867 Spectrophetometer                6/25/96        01         4,418     -1,740     2,678      -219
F51868 Balance (Gram)                   6/25/96        01         2,535     -1,038     1,597      -131
F41869 Balance (Miligram)               6/25/96        01         1,874       -738     1,136       -93
F41870 Centrifuge                       6/25/96        01         1,731       -681     1,050       -86
F41871 Shaker/Mixer/Vortex              6/25/96        01           791       -311       480       -39
F41873 Building Improve - Fixture       6/25/96        01         1,715       -675     1,040       -85
F41875 Centrifuge                       6/25/96        01         8,570     -3,374     5,196      -425
F41877 DNA Sequencer                    6/25/96        01       117,455    -46,245    71,210    -5,822
F41878 Printer                          6/25/96        01         4,889     -1,925     2,954      -242
F41897 Fluorometer                      6/25/96        01         2,239       -852     1,387      -113
F41898 Refrigerator                     6/25/96        01         6,536     -2,488     4,048      -331
F41899 Centrifuge                       6/25/96        01         2,563       -976     1,587      -130
F41900 Centrifuge                       6/25/96        01         2,563       -976     1,587      -130
F41901 475 W Ultrasonic Cell Dis        6/25/96        01         2,627     -1,000     1,627      -133
F41902 Centrifuge                       6/25/96        01         3,055     -1,153     1,892      -155
F41909 Refrigerator                     6/25/96        01         1,761       -670     1,091       -89
F41910 Refrigerator                     6/25/96        01         1,761       -670     1,091       -89
F71181 DNA Thermal Cycler               6/25/96        01         6,185     -2,677     3,508      -287
F71182 DNA Thermal Cycler               6/25/96        01         6,185     -2,677     3,508      -287
F71183 Personal Computer                6/25/96        01         5,095     -4,303       792      -481
F71673 Freezer Ultra Low Temp           6/25/96        01         5,086     -2,135     2,951      -241
F84699 Personal Computer                6/25/96        01         3,047     -1,972     1,075      -315
F84700 Monitor                          6/25/96        01           522       -338       184       -54
F94097 Centrifuge                       6/25/96        01         1,813       -573     1,240       -89
F94743 Centrifuge                       6/25/96        01         5,623     -2,007     3,616      -296
F95220 Water Bath                       6/25/96        01           378       -128       250       -18
F95221 Water Bath                       6/25/96        01           378       -128       250       -18
F95222 Water Bath                       6/25/96        01           301       -102       199       -14
F95223 Water Bath                       6/25/96        01         2,858       -969     1,889      -135
F95387 Freezer                          6/25/96        01         9,331     -3,358     5,973      -427
F95425 Printer                          6/25/96        01           861       -322       539       -39
F95541 Freezer                          6/25/96        01         5,005      1,737     3,568      -255
F95686 Pump - Dynamex                   6/25/96        01        48,384    -14,520    33,864    -2,420
F96892 Pipettor                         6/25/96        01         1,278       -389       889       -64
F98993 Incubator                        6/25/96        01        10,229     -3,235     6,994      -500
</TABLE>

<PAGE>   174
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------
SB R&D - Upper Merion, USA
                                          Date      Dep      Asset      Accum                  YTD
Description                             Acquired    Met      Cost       Deprec      NBV       Deprec
----------------------------------------------------------------------------------------------------
<S>                                    <C>           <C>    <C>        <C>        <C>         <C>
F99172 Water Bath                       6/25/96      01       1,864       -402      1,462      -104
F99196 Flucrometer                      6/25/96      01       2,456       -662      1,794      -125
F99298 Pipettor                         6/25/96      01       1,272       -343        929       -66
038669 EDP Plus Micro                   9/17/96      01       1,336       -358        978      -189
038710 Magneto Optical Drive            9/10/96      01       2,476       -663      1,813      -351
038794 Gene AMP PCR System              9/10/96      01       9,609     -1,029      8,580      -545
038796 Multiprobe 204DT Base Uni        9/10/96      01      47,415    -12,689     34,726    -6,718
039031 EDP Plus Micro                  11/20/96      01       1,588       -425      1,163       225
039307 PBA Fiery Sys W/Hotel            8/10/97      01     134,547          0    134,547         0
039455 Apex4 - 6GBPC                    5/11/97      01       3,266        -58      3,208       -58
039550 HP DeskJet 1600 Printer         10/16/96      01       1,929       -516      1,413      -273
040960 Duo Therm Hybridization O        5/11/97      01       3,885        -28      3,857       -28
040961 Duo Therm Hybridization O        5/11/97      01       3,885        -28      3,857       -28
041485 Micro Centrifuge Model 54        5/11/97      01       1,658        -12      1,646       -12
041486 Micro Centrifuge Model 54        5/11/97      01       1,658        -12      1,646       -12
041487 Micro Centrifuge Model 54        5/11/97      01       1,658        -12      1,646       -12
041561 Silverscanner III W/Photo        5/11/97      01       1,792        -13      1,779       -13
041764 ABI Prism DNA Sequencer          5/11/97      01     130,096       -926    129,172      -926
041901 Centrifuge Refrigerated G        7/13/97      01      10,500        -77     10,723       -77
041902 DU 6408 UV/VIS Scanning          5/11/97      01      11,627        -83     11,544       -83
041903 Auto Microplate Shaking W        5/11/97      01       6,461        -46      6,415       -46
041904 Auto Microplate Shaking W        5/11/97      01       6,461        -46      6,415       -46
041905 Spectramax 250 Windows Sy        5/11/97      01      28,250       -201     28,049      -201
041906 DNA Sequencer 373XLGS            5/11/97      01      17,471       -124     17,347      -124
041907 DNA Sequencer 377XL UPGRA        5/11/97      01      15,025       -107     14,918      -107
041908 Geneamp PCR System 9600          5/11/97      01       9,528        -68      9,460       -68
041909 Geneamp PCR System 9600          5/11/97      01       9,528        -68      9,460       -68
041910 Geneamp PCR System 9600          5/11/97      01       9,528        -68      9,460       -68
041911 Geneamp PCR System 9600          5/11/97      01       9,528        -68      9,460       -68
041912 Eagle Eye Imaging System         5/11/97      01      17,430       -124     17,306      -124
041913 Tekmar Tissue Homogenizer        7/13/97      01       1,788        -13      1,775       -13
041914 Refrigerated Incubator IT        5/11/97      01       4,265        -30      4,235       -30
041915 Micro Centrifuge 20901-05        7/13/97      01       1,658        -12      1,646       -12
041933 Flowcell 4 & .15mm Superp        5/11/97      01       1,808        -13      1,795       -13
041966 Polytron Homogenizer PT31        7/13/97      01       5,092        -36      5,056       -36
042114 DNA Sequencer Model 377          5/11/97      01     124,371       -885    123,486      -885
042222 Compaq Deskpro 5133 M2000        5/11/97      01       2,880        -51      2,829       -51
042233 Screen & Cassette Large          5/11/97      01       1,906        -14      1,892       -14
042234 Screen & Cassette Large          5/11/97      01       1,906        -14      1,892       -14
042235 Screen & Cassette Large          5/11/97      01       1,906        -14      1,892       -14
042236 Screen & Cassette Large          5/11/97      01       1,906        -14      1,892       -14
042240 Sequence Detector Model 7        5/11/97      01      85,488       -609     84,879      -609
042247 HP 1600cm Printer                5/11/97      01       2,600        -19      2,581       -19
042331 Water Bath for DNA Sequen        7/13/97      01       2,771        -20      2,751       -20
042332 Water Bath for DNA Sequen        7/13/97      01       2,771        -20      2,751       -20
042448 Fluorometer Wallac 12345         5/11/97      01      28,700       -204     28,496      -204
042487 Sequencer 3.0                    5/11/97      01       2,613        -19      2,594       -19
----------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>   175
                        Schedule 1.1(b) -- SB Employees

<TABLE>
<CAPTION>
<S>                                <C>
NAME                               TITLE

Burczak, John, Dr.                 Director

Tamura, James, Dr.                 Sr. Investigator

Cafferkey, Robert, Dr.             Sr. Investigator

Macina, Roberto, Dr.               Sr. Investigator

Wilkinson, Francis E., Dr.         Investigator

Wang, Xin Min                      Sr. Scientist

Rood-Breithaupt, Julie             Assoc. Investigator

Stawicki, Mary E.                  Assoc. Investigator

Bennett, Donald                    Scientist

Xiong, Wenfang Chen                Scientist

Ling, Ching Y.                     Scientist

Qu Li, Kathleen                    Scientist

Plewman, Patrick                   Vice President, Business Development
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]